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BacqroUDd

As a recipient otthe Univenity ofTenucssee. Knoxvillc·s Whittle Scholarship. one ormy

requirements for graduation is the completion of a University Honors Program senior project As outlined in
the University Honors Program Student Handboo/c. the ~uior project is "lUI opportunity for each honors
student to become ensased in reaearcb or creative activity tbal marks a capstone of the undergraduate
experience." Although a large portion of senior projects relate 10 the studcntts field of study, the University
Honors DepQJ1menl does not require tllat a student complete hiSlher project in hiSlher academic major. This
loose constraint alloWl'i stu.dc:nb to explore new areu and &0 learn things they otherwise would not have studied
in schooL BecaWie of the extreme scope these senior projects can be focused on, the University Honors

Department bas inCOrporllted Il few general requirements to qualify Il student's work 6.0; a senior project.
The fu-st requirement tor a student to complete is to select and recruit 11 fllCulty mentor. As the
primary purpose of the faculty mentor is to assist and guide the .student along his/her senior project. a faculty
mentor should be knowledgeable in tha project's subject and Ilcccssiblc to the student. Sclt.'Cting a faculty
mentor is a crucial part of the senior project for helshe will have to approve the initial senior project
prospectus. to review and edit drafts ofthc project, and to approve the final draft for submission as a senior
project After selecting Il faculty mentor. the second requirement of a senior project is to enroll in the senior
projt:ct 15(.:mmar, a one-how- clllSS taught by the University Honors' dcporLmenL head. Although this class is

designed aroWld the senior project, its empbuis is not on completmg the senior prQjecl. but rather to as..;st
students in selecting. researching, aDd beginning their senior projects, to expose students to various other
academic interests. and &0 provide students the opportunity to deliver professional anu presentations,
Recosnjzing that many academic majors also require some type of senior resePlcn or senior design project to
culminate a student·s underaraduate experience. the University Honors Department provides a method, listed
in the University Honors Program Student Handbook,

to complete both requirements with

a single project:

"If a student wishes to use some part of a senior non-honors or group project as the student's senior hOllors

project, the additional effort should be clearly defmed on the •Senior Project Approval,' and pennission should
be obtuincd from the University HOllars Office,"' Upon completion of these requirements for a University
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Honors senior projecl, students should finish a work that can be placed upon their resumes and discussed with
prospccti ve employers or admissioo.s boards.

Purpulc

The purpose of this paper is 10 ada.pt my nuclear engineering senior design project. UDesign of a
Clinical Boron Neutron Capture Therapy Treatmenl Facility." to the constraints ond qualifications necessary to
~tisry the requirements of a University Honors Program"s senior project

In order to accomplish this goal. the

remainder of this paper will focus on explainina the project in a non-technical fashion. the mclbods used by my
group to complete the design project. my personal contributions to the design project. and my insights and

opinions on the design project

DOIign of a Clinical Boroo Neutron Capture Thenpy (BNC1) Treatment Facility - a projeet
explanation
8NCT is an ideo concerning the treatment and destruction offormerly inoperable tumors. Patients un:
given a solution of boron which is readily absorbed by and concentrated in the maHgnant tumor cells. Upon
being exposed to Q stream of neutrons. a boron atom will absorb a neutron and split into two particles. The

separation. or fission. of the boron atom will generate enough energy to kill the malignant cell without harming
the surrounding bealthy cells. However. this process is far more difficult than it first appears. Not only must a
neutron collide with a boron atom, that neutron must have a CCltain energy level when the collision occurs. If
the energy level of the neutron is too high or too low, the desired separation of the boron atom will not occur.
As neutrons must not only engage boron atoms but engage them i.1l a specific energy range. my design

proj ~ct focuses primarily on changing the energy of the neutrons when they AlTAVe at the boron atoms. and
secondly on designing a BNCT treatment center layout As one possible source of neutrons for BNCT. Oak
Ridge National Lab's Tower Shielding RePCtor (TSR}.lies within a short drive nom Knoxville, my class's goal
would be [0 dcsjgn the trcalrnent facility lit the TSR and apply the IIbove foci. The results tlIld further
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explantttion of the project is contained in our final draft. "Design of a Clinical Boron Neutron Capture Therapy

Treatment Facility. ,.

Group Method! to Facilitate Project Completion
Selected from the students cw'OUed in the Sprins 1996 section of Nuclear Engineering 472~ my design
group consisted of six students; Chet Rwnsey, Cindy Maples. Don Marsh. Anne Robinson-Silber, Randy
Hooker, und myself. Once we were assigned to groups. our first tASk was to decide how we wanted to approach
UUs project. Following much discussion. we decided that we would begin oW" research by gaining an
undcrslunding of the history behmd BNCT IUld the TSR. Once comf'orw.ble with the bllSic tenninology

WlSociatcci with BNCT and the TSR, we besou our second task. deciding upon the scope and orsouization of
our work. Over the COlD"SC of the next few weeks. we nllITowed down the scope of OUT project to include the

design of a shutter and collimator system for the ISK. &9 well as a design for the treatment facility. Eventually,
we broke it down into fifteen basic elements. listed in section 1.4 of "Dcsisn of u Clinical Boron Neutron
Capture Therapy Treatmenr Facility." We then assigned group members to work in vru'ious categories
according to hislher interests and skills. Around this time in the project we decided that ill order to promote
efficiency amol1S the group that we would ueed to appoint group leuder. Although the group leader would be
expected to assist IIIld to assign work to other team members, he/she would also have to pl..'Ttorm duties of
hislher own. which weighed heavily upon our decision when electing 8 member to this position. Eventually,

Chet Ramsey was uppointed our group leuder. After breaking down the projcct and uSbigning group members
to specific tasks, the final, and most difficult aspect, of our project was to accumulute all of tbe infonnation we
had collected and insert it into a report fashion. This proved to be troublesome as combillin& the tbouahts und

ideas of six unique individuals is a combination of much time and putience.

Penonal Contribution" to Ih. Gro"p Project

In addition to perfonning some coqunon tasks of the group (e.g., background research. report editing.

und report writing). I concentrated my efforts primarily on Lbe economic, licensing. and mechanical design
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aspects of our desip. project. Obtaining estimates OD the construction of the BNCT facility. discussing and
detennining necessary equipment and personnel for the facility. collecting estimuld on the equipment und

personnel, determining approximate cost of treatment, estimating start-up. mWntcnmcc, operating. and
decommissioning costs, and determining the cost of licensing the facility were primary interests in the
economic analysis of our design. In order La accomplish these tasks. I bad to COlltoct multiple individuals who

were knowledgeable on many different subjects. For instance. to obtain an estimate for the construction of our
proposed facility. I discussed the floor plans with Randy and Cindy to determine the absolute necessary

components for conS1rUCtion (e.g., the treatment room must have concrete walls) and then spoke with different
contrllctors who would be able to bid on SlWb a job. In order to determine what equipment and personnel

would be necC5.'ml'Y to operate such a facility. I spoke with several chemists, doctors, and nurses who provided
yaluable opinion:;. After deciding whot we needed, I then had to contact distributors of the equipment to obtain
estimates. Much of my time was Itlso spent discussing the estimated sturt-up, maintenance. shutdo'Wtl. and

deconunissioning costs with sevetal individuals at Tennessee Center tor Resetirch and Development. 1'1
Knoxville company CWTently working on a feasibility study for a BNCT treatment facility at the TSR.
In addition to the economic research, I invested a great deal of time in (&!Sew-ching the licensing

a.<;pects of our design. The majority of this research was done over the phone, conversing with individuals at
the Oak Ridge NiltionPl L{1b. the DelllU1ment ofEnel'gy. W'ld other govemment organizations. In addition to the
multipJe conversations, 1spent time reading stIme government regulations that were delermined Lo be of

primtuy importance to our design. Although much research W{I.$ put into the licensing necessary to operate our

proposed BNCT treatment facility, a lurse portion WPS left for future work wltil greoter detaiJs about the fACility
are available.

Not all of my contributions to the proj ect were in the form of pW'C research and persistence. as I was
also Involved with the mechanical design of the shutter/collimator system. This gove me an opportunity to
implement some of the critical thinking skills that are so necessary to engineering, Alk'f discussing the pros

and COPS ofmWlY idcu. we decided that rather than modify the existing system 81 the TSR, we would design It
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entirely new ~j'5tem. Mucb ofmy personal contribution to this facet of the design projcct revolved aroWld.
intrinsic safety features and stability of the system.

Opinion! and IDsigbb about tbo DelllU Projeet

Overall. I fOWld this design project to be 1m interesting IlI1d informative endeavor. Although we did
not have the opporlunity to cboo..~ oW' own project, designing a ENeT treatment facility was an excellent

choice because it was able to combine traditional facets of nuclear engineering (e.g.• neutron transport) with the
health physics/medical side of nuclcur engineering. This not only peaked dift'erent mterests in our group_ but
also forced us to become more dynamic in our thinking. Requiring cvcry1hing from libruy research to

computer simulations to personal inquiries. the projcct look the Conn of Ureal world" engineering.
Although the technical skills developed and information acquired I1lay prove useful in the future, the
most important skills developed dw'ing this project come from the challenge of six individuals attempting to
work together as one team. Through this experience. I gained insishl on how important corrununication was to

the group's success. how different individuals express their thoushts and opinions in different WIl}'S. how
utilizing the talents of different individuals can lead to grealer efficiency. how diJicrcnl people arc productive in

different settings, and many other things. Participatmg in this group gove me: fW1her conviction as to the
importance of being able to communicate and listen LO others, no matter what field I enLer.
Even with the success of my project. ifl had to do it again there arc a few ChWlgt.--S I would 8ltempt to
implement. First of aU. r would definitely begin the research earlier. Althouib a last minute alteration may not
be Ilble to be avoided, I can not stress enough the importance of pllCing yourself throughout the semester. Not
only

wm this lend Lo a project of higher quality. il will also make the project more \'-njoyablu.

Scroondly. I would

attempt Lo get involved in almost all of the laccLs of the: projcct. Once ag&in. the greater YOUt involvement in

the projL"Cl. the more you will enjoy and learn from it. Finally. 1would not hesitate {O contaot people who have
oll'Crcd Lo help you and even those that have not I WDS smpriscd at how much information CUll be obtained

with u lin1c cxplanation ot'my project along with a tew "please md thlillk you"s. More times than not people
were willing to go out oftbeir wily to help me with the project
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Background
As a recipient of the University of Tennessee, Knoxville's Whittle Scholarship, one of my

requirements for graduation is the completion of a University Honors Program senior project. As outlined in
the University Honors Program Student Handbook, the senior project is "an opportunity for each honors
student to become engaged in research or creative activity that marks a capstone of the undergraduate
experience." Although a large portion of senior projects relate to the student's field of study, the University
Honors Department does not require that a student complete his/her project in his/her academic major. This
loose constraint allows students to explore new areas and to learn things they otherwise would not have studied
in school. Because of the extreme scope these senior projects can be focused on, the University Honors
Department has incorporated a few general requirements to qualify a student's work as a senior project.
The first requirement for a student to complete is to select and recruit a faculty mentor. As the
primary purpose of the faculty mentor is to assist and guide the student along hislher senior project, a faculty
mentor should be knowledgeable in the project's subject and accessible to the student. Selecting a faculty
mentor is a crucial part of the senior project for he/she will have to approve the initial senior project
prospectus, to review and edit drafts of the project, and to approve the final draft for submission as a senior
project. After selecting a faculty mentor, the second requirement of a senior project is to enroll in the senior
project seminar, a one-hour class taught by the University Honors' department head. Although this class is
designed around the senior project, its emphasis is not on completing the senior project, but rather to assist
students in selecting, researching. and beginning their senior projects, to expose students to various other
academic interests, and to provide students the opportunity to deliver professional oral presentations.
Recognizing that many academic majors also require some type of senior research or senior design project to
culminate a student's undergraduate experience, the University Honors Department provides a method, listed
in the University Honors Program Student Handbook, to complete both requirements with a single project:
"If a student wishes to use some part of a senior non-honors or group project as the student's senior honors
project, the additional effort should be clearly defmed on the 'Senior Project Approval: and permission should
be obtained from the University Honors Office." Upon completion of these requirements for a University

1

Honors senior project, students should finish a work that can be placed upon their resumes and discussed with
prospective employers or admissions boards.

Purpose

The purpose of this paper is to adapt my nuclear engineering senior design project, "Design of a
Clinical Boron Neutron Capture Therapy Treatment Facility," to the constraints and qualifications necessary to
satisfy the requirements of a University Honors Program's senior project. In order to accomplish this goal, the
remainder of this paper will focus on explaining the project in a non-technical fashion, the methods used by my
group to complete the design project, my personal contributions to the design project, and my insights and
opinions on the design project.

Design of a Clinical Boron Neutron Capture Therapy (BNCT) Treatment Facility - a project
explanation

BNCT is an idea concerning the treatment and destruction offonnerly inoperable tumors. Patients are
given a solution of boron which is readily absorbed by and concentrated in the malignant tumor cells. Upon
being exposed to a stream of neutrons, a boron atom will absorb a neutron and split into two particles. The
separation, or fission, of the boron atom will generate enough energy to kill the malignant cell without hanning
the surrounding healthy cells. However, this process is far more difficult than it first appears. Not only must a
neutron collide with a boron atom, that neutron must have a certain energy level when the collision occurs. If
the energy level of the neutron is too high or too low, the desired separation of the boron atom will not occur.
As neutrons must not only engage boron atoms but engage them in a specific energy range, my design
project focuses primarily on changing the energy of the neutrons when they arrive at the boron atoms, and
secondly on designing a BNCT treatment center layout. As one possible source of neutrons for BNCT, Oak
Ridge National Lab's Tower Shielding Reactor (TSR), lies within a short drive from Knoxville, my class's goal
would be to design the treatment facility at the TSR and apply the above foci. The results and further
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explanation ofthe project is contained in our final draft, "Design of a Clinical Boron Neutron Capture Therapy
Treatment Facility."

Group Methods to Facilitate Project Completion

Selected from the students enrolled in the Spring 1996 section of Nuclear Engineering 472, my design
group consisted of six students: Chet Ramsey, Cindy Maples, Don Marsh, Anne Robinson-Silber, Randy
Hooker, and myself Once we were assigned to groups, our first task was to decide how we wanted to approach
this project. Following much discussion, we decided that we would begin our research by gaining an
understanding of the history behind BNCT and the TSR. Once comfortable with the basic terminology
associated with BNCT and the TSR, we began our second task, deciding upon the scope and organization of
our work. Over the course of the next few weeks, we narrowed down the scope of our project to include the
design of a shutter and collimator system for the TSR, as well as a design for the treatment facility. Eventually,
we broke it down into fifteen basic elements, listed in section 1.4 of "Design of a Clinical Boron Neutron
Capture Therapy Treatment Facility." We then assigned group members to work in various categories
according to hislher interests and skills. Around this time in the project we decided that in order to promote
efficiency among the group that we would need to appoint group leader. Although the group leader would be
expected to assist and to assign work to other team members, he/she would also have to perform duties of
hislher own, which weighed heavily upon our decision when electing a member to this position. Eventually,
Chet Ramsey was appointed our group leader. After breaking down the project and assigning group members
to specific tasks, the final, and most difficult aspect, of our project was to accumulate all of the information we
had collected and insert it into a report fashion. This proved to be troublesome as combining the thoughts and
ideas of six unique individuals is a combination of much time and patience.

Personal Contributions to the Group Project

In addition to performing some common tasks of the group (e.g., background research, report editing,
and report writing), I concentrated my efforts primarily on the economic, licensing, and mechanical design

3

aspects of our design project. Obtaining estimates on the construction of the BNCT facility, discussing and
detennining necessary equipment and personnel for the facility, collecting estimates on the equipment and
personnel, determining approximate cost of treatment, estimating start-up, maintenance, operating, and
decommissioning costs, and determining the cost of licensing the facility were primary interests in the
economic analysis of our design. In order to accomplish these tasks, I had to contact multiple individuals who
were knowledgeable on many different SUbjects. For instance, to obtain an estimate for the construction of our
proposed facility, I discussed the floor plans with Randy and Cindy to determine the absolute necessary
components for construction (e.g., the treatment room must have concrete walls) and then spoke with different
contractors who would be able to bid on such ajob. In order to determine what equipment and personnel
would be necessary to operate such a facility, I spoke with several chemists, doctors, and nurses who provided
valuable opinions. After deciding what we needed, I then had to contact distributors of the equipment to obtain
estimates. Much of my time was also spent discussing the estimated start-up, maintenance, shutdown, and
decommissioning costs with several individuals at Tennessee Center for Research and Development, a
Knoxville company currently working on a feasibility study for a BNCT treatment facility at the TSR.
In addition to the economic research, I invested a great deal of time in researching the licensing
aspects of our design. The majority of this research was done over the phone, conversing with individuals at
the Oak Ridge National Lab, the Department of Energy, and other government organizations. In addition to the
multiple conversations, I spent time reading some government regulations that were determined to be of
primary importance to our design. Although much research was put into the licensing necessary to operate our
proposed BNCT treatment facility, a large portion was left for future work until greater details about the facility
are available.
Not all of my contributions to the project were in the form of pure research and persistence, as I was
also involved with the mechanical design of the shutter/collimator system. This gave me an opportunity to
implement some of the critical thinking skills that are so necessary to engineering. After discussing the pros
and cons of many ideas, we decided that rather than modifY the existing system at the TSR, we would design a
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entirely new system. Much of my personal contribution to this facet of the design project revolved around
intrinsic safety features and stability of the system.

Opinions and Insights about the Design Project
Overall, I found this design project to be an interesting and informative endeavor. Although we did
not have the opportunity to choose our own project, designing a BNCT treatment facility was an excellent
choice because it was able to combine traditional facets of nuclear engineering (e.g., neutron transport) with the
health physics/medical side of nuclear engineering. This not only peaked different interests in our group, but
also forced us to become more dynamic in our thinking. Requiring everything from library research to
computer simulations to personal inquiries, the project took the form of "real world" engineering.
Although the technical skills developed and information acquired may prove useful in the future, the
most important skills developed during this project came from the challenge of six individuals attempting to
work together as one team. Through this experience, I gained insight on how important communication was to
the group' s success, how different individuals express their thoughts and opinions in different ways, how
utilizing the talents of different individuals can lead to greater efficiency, how different people are productive in
different settings, and many other things. Participating in this group gave me further conviction as to the
importance of being able to communicate and listen to others, no matter what field I enter.
Even with the success of my project, if I had to do it again there are a few changes I would attempt to
implement. First of all, I would definitely begin the research earlier. Although a last minute alteration may not
be able to be avoided, I can not stress enough the importance of pacing yourself throughout the semester. Not
only will this lead to a project of higher quality, it will also make the project more enjoyable. Secondly, I would
attempt to get involved in almost all of the facets of the project. Once again, the greater your involvement in
the project, the more you will enjoy and learn from it. Finally, I would not hesitate to contact people who have
offered to help you and even those that have not. I was surprised at how much information can be obtained
with a little explanation of my project along with a few "please and thank you"s. More times than not people
were willing to go out of their way to help me with the project.
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Abstract
The goal of this design project is to develop a conceptual design ofa clinical
facility for Boron Neutron Capture Therapy that utilizes Oak Ridge National Laboratory's
Tower Shielding Reactor as the neutron source. The primary focus of this report is to
develop an overall facility design as well as designs for a conceptual beam collimator and
beam shutter. Additionally, system safety and facility economics are addressed.
The overall facility design includes treatment rooms::> a confinement building, and
supporting medical facilities. The medical facilities support the outpatient treatment of
cancer patients in a comfortable environment. The treatment room and confinement
building provide protection for the patients, environment, and personnel during normal
and abnormal operations. Facility economics are evaluated for startup, maintenance::>
operating, and decommissioning costs as well as income generated from treating patients.

Table of Contents
1. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . ................. 1
1.1 Background .................................................. l
].2 Design Objectives ........................................... 3
1.3 Scope and Organization of Work ........................ .4
1.4 Work Breakdown Structure ............................... 5
2. BNCT History .................................... " .................. 7
2.1 Initial Clinical Trials ........................................ 7
2.2 Boron Chemistry ............................................. 8
2.3 Current Clinical Trials............... ................... .10
3. Site Selection ......................................................... 12
3.1 Neutron Sources ............................................ 12
3.2 Possible Reactor Sites in the U.S ......................... 13
3.3 Possible Reactor Sites at ORNL .......................... 14
3.4 The Tower Shielding Facility .............................. 16
3.5 TSR Core Region ........................................... 18
3.6 Core Heat Transfer ......................................... 19
4. Beam Shutter Design... '" ........................................... 21
4.1 Description of System and Operation .................... 22
4.2 Interchangeable Filter Design.............................. 25
4.3 Safety Features ................................ , ............. 26
4.4 Hydraulic System Specifics ................................ 26
5. Shutter Design ................................ , ....................... 29
5.1 Shutter Calculations ................................... , .... 29
5.2 Detailed Description of Shutter Design ................. .30
6. Collimator Design .................................................... 32
6.1 Collimator Modeling and Calculations .................. .32
6.2 Programs to Analyze DORT Output ............... '" ... 33
6.3 Collimator Optimization .................................... 35
6.4 Detained Collimator Design ................................ 43
7. Clinical Facility Design ............ " ................................ 47
7.1 Site Location ................................................. 47
7.2 Present Tower and Facility Layout ........................ 47
7.3 Proposed Additions ......................................... .49
7.4 Optional Thermal Treatment Room ....................... 53
7.5 Treatment Sequence ....................................... 54
7.6 Filtration System ............................................ 55
7.7 Reactor Coolant System .................................. 56
7.8 Future Expansion ........................................... .57
8. Conclusions ........................................................... 58
9. Future Work ................. , ........................................ 59

Appendix AI.I... . . . .. . . . . .. . . . . . . . ... .. . . . . ... . . . . . .. . ........................ .60
Appendix AI.2 ... ......... '" .................................................... 73
Appendix AI.2 ... ........................................ " ..................... .84
Appendix 2 ..................................................................... 102

Chapter 1
Introduction
1.1 Background
In the United States 1,515 people die every day from all types of cancer. 22 At
present, the only way to survive is with an effective treatment, but with some forms of
cancer there is none. An ideal treatment for cancer would ignore normal cells while
simultaneously seeking out and destroying rapidly dividing cells. 3 With today's medical,
chemical, and nuclear technology, a procedure based on these principles has been
successfully administered.
Boron neutron capture therapy (BNCT) is a treatment that brings together two
components that individually have little effect on normal tissue. The first component is a
chemical compound that contains the stable isotope boron-I 0, and the second is a beam of
neutrons. When injected into the body, the chemical compound will concentrate in
cancerous cells. After a short period of time, the boron compound is biologically removed
from normal tissue. When the boron-I 0 absorbs neutrons it subsequently decays by alpha
emission. The alpha particle and the recoiling lithium atom deposit most of their energy
inside the cell containing the original boron. 2 The result of this reaction is a deadly
radiation field of heavy particles localized to tumor cells as shown in Figure 1. 1. ·17

Although treatment such as surgery, chemotherapy, and radiation have successfully
treated many types of cancer, there are
some forms for which BNCT is the only
solution. One of the most highly malignant
and resistant of all cancers is Glioblasoma
Multiform (GBM). GBM is a cancer of
the glial supportive tissue of the central
nervous system (CNS). Glial cells, which
Figure 1. 1 Schematic of the Boron-IO Neutron

make up over 90 percent of the CNS,

Interaction

provide chemical and physical support to neurons. Unlike neurons, glial cells are extremely
susceptible to cancer because they are constantly undergoing mitosis. The standard
treatment for GBM is an external beam of 4 to 6 MeV X-rays, given in doses of
approximately 60 Gy administered in fractions of 1.8 to 2.0 Gy daily five days a week. 31
Unfortunately, this method destroys much of the intervening healthy brain tissue in the
beam path, and unless every cancer cell is killed, there is a possibility that the cancer will
reestablish itself The median survival rate for treated GBM ranges from eight to fourteen
months while untreated GBM results in a median survival rate of three months.
During 1995, approximately 323,000 people in the United States died from brain,
colon, skin, lung, breast, and prostrate cancer, all of which could have been treated with
BNCT. Ifproven effective:> over 90,000 patients yr-l could qualify for BNCT. The life
extension and higher quality of life beyond conventional treatments could potentially
return over $73 billion to the U.S. Treasury over a 10 year period. 14

2

1.2 Design Objectives
The goal of this design project is to develop a conceptual design of a clinical
facility for Boron Neutron Capture Therapy that utilizes Oak Ridge National Laboratory's
(ORNL) Tower Shielding Reactor (TSR) as the neutron source. The primary focus of this
proj ect is to develop an overall facility design as well as designs for a conceptual beam
collimator and beam shutter. Additionally, system safety and facility economics will be
addressed by the final design.
The beam collimator should be designed in order to maximize the dose delivered to
the tumor and minimize the dose delivered to the rest of the body by varying the diameter,
thickness, material, and angle of the collimator as shown in Figure 1. 2. The neutron

Figure 1.2 Collimator Design Parameters

fluence incident on the collimator is anisotropic and equally distributed across its surface.
In order to minimize radiation exposure to the body, the neutron leakage from the reactor
is collimated into a narrow beam.
In order to maximize the number of patients treated daily and reduce stress on the
reactor core, the reactor will not shut down between treatments. A shutter should be
designed to reduce the radiation exposure in the treatment room to levels as low as
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reasonably achievable, thus allowing unrestricted entry for attending personnel. The
shutter design should also contain a safety system to insure closure during both normal
and credible abnonnal operations.
The overall facility design includes treatment rooms, a confinement building, and
supporting nledical facilities. The medical facilities will support the outpatient treatment of
cancer patients in a comfortable environment. The treatment room and confinement
building will provide protection for the patients, environment, and personnel during
normal and abnormal operations. Facility economics will also be evaluated for startup,
maintenance, operating, and decommissioning costs as well as income generated from
treating patients.

1.3 Scope and Organization of Work
Chapter 2 of this report summarizes the history and previous research that has
gone into making boron neutron capture therapy a viable treatment method. This section
also summarizes the work that has gone into boron chemistry, animal testing, and clinical
trials.
Chapter 3 describes the selection process for finding an appropriate neutron
source. The advantages and disadvantages of different types of neutron sources are
discussed. The final selection of the Tower Shielding Reactor is also discussed.
Chapter 4 summarizes the design of the hydraulics used to move the shutter.
Safety systems and interchangeable filters are also discussed.

4

Chapter 5 summarizes the design of the shutter for the neutron beam. This section
discusses the materials chosen for the shield.
Chapter 6 summarizes the design of the collimator for the epithelIDal beam. This
section also discusses the materials and geometry chosen for the fabrication of the
collimator.
Chapter 7 summarizes the design of the facility including the medical, chemical,
and nuclear aspects. Related equipment required for standard operations and safety are
also discussed. Additionally, suppliers and cost estimates for the overall facility and related
equipment are also given in Chapter 7.
The complete facility design is provided in Chapter 8. A total cost estimate for the
start-up, maintenance, operating, and decommissioning is discussed. Treatment cost and
revenue generated are also discussed in Chapter 8.
Chapter 9 describes work that needs to be considered for the future.

1.4 Work Breakdown Structure
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Chapter 2
BNCT History
2.1 lnitial Clinical Trials

15

The therapeutic potential of boron neutron capture therapy is not a new idea. It
was a dream first conceptualized in 1936 by G.L. Locher of the Franklin Institute:- but
was not given form until 1951 by W.H. Sweet. Sweet and his collea!,lUes first
demonstrated that the chemical compound borax would concentrate in tumor cells in the
human brain. Shortly thereafter:- clinical trials were initiated at the Brookhaven National
Laboratory (BNL) in conjunction with the Massachusetts General Hospital. The trials at
BNL were carried out from 1951 to 1952 and additional trials were carried out from 1961
to 1962 at the Massachusetts Institute of Technology (MIT). Unfortunately, the trials
failed to show any therapeutic advantage, and in some cases, actually shortened the
patient's life. The first boron compounds used did not achieve selective localization in the
tumor due to their diffusibility and low molecular weight. This, combined with a beam of
thermal neutrons that was rapidly attenuated in tissue, resulted in massive damage to
adjacent skin and brain.
Fortunately, one of the researchers, H. Hatanaka, returned to Japan to continue
working on boron neutron capture therapy. Dr. Hatanaka treated over a hundred patients
with a wide variety of tumor grades and history with promising results:- as shown in Figure
2.1. Group 1 represents 46 patients who received chemotherapy and radiation treatment

7

before their BNCT treatment. Group 2 represents all 38 patients that received only BNCT
between 1968 and 1985. Group 3 represents the twelve BNCT patients with
tumors less than six centimeters from the surface of the brain. Group 4 represents the
eleven patients treated between 1987 and 1989. The five year survival rate for Group 3
patients was 58.3 percent and 68 percent for Group 4. The five year survival rate with
conventional surgery, chemotherapy, and radiotherapy was 4.6 percent.

2.2 Boron Chemistry23
Several nuclides have high cross sections for therrnal neutrons, but boron-lOis the
only one that is ideally suited for BNCT. Boron-lOis not radioactive and is readily
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Figure 2. 1 Hatanaka Data

available, comprising approximately 20 percent of naturally occurring boron. The particles
8

emitted by the neutron capture reaction l~(n,afLi have a high Linear Energy Transfer
(LET), and their path lengths are approximately one cell diameter (10 microns). This
effect theoretically limits the radiation damage to tumor cells that have taken up a
sufficient amount of boron-l O. Another advantage of boron-lOis that the alpha particles
can kill dividing and non dividing cells alike. This is important because tumors are known
to have a large number of viable but inactive cells, and other fonns of radiation treatment
and chemotherapy work best only on ceJls that are dividing.
Boron compounds used in BNCT have a high specificity for malignant cells with
low concentrations in normal tissue and blood.

10

Initially, boron compounds such as

sodium borate and boric acid were selected for their availability, known pharmacology,
and lack of toxicity. The differences in the concentration between the tumor and brain for
these chemicals, which was small to begin with, dissipated over a period of 1 to 2 hours.
These shortcomings prompted a major effort in boron chemistry, which resulted in over a
hundred compounds being screened. 6 Eventually, p-carboxybenzeneboronic acid and
sodium decahydrodecaborate were selected for the first clinical trials at MlT.
Researchers at Shionogi Research Laboratories developed and synthesized the
compound Na2B 12H ll SH, also known as BSH,. for use in BNCT. 18 Dr. Hatanaka
determined boron uptake by surgically collecting tissue samples from 57 patients. These
patients received BSH doses of 30 to 80 mg per kilogram of body weight approximately
twelve hours before neutron irradiation. The average concentration was 26.3 ppm in the
tumor and 18.2 ppm in the blood, and the mean tumor to blood ratio was 1.69.

9

Recently> there has been an increasing interest in the boron containing amino acid
boronophenylalanine (BPA).l1 In Japan, BPA was used as a capture agent for BNCT of
melanomas in both humans and animals?4 BPA has a very low toxicity, a high affinity to
tumor calls, a tumor-to-blood ratio of3.5, and a tumor-to-brain ratio of3.9.

28

It is these

characteristics that make clinical BNCT possible. 4

2.3 Current Clinical Trials25
Dr. Hatanaka's patients are treated with a thetmal neutron beam that has a
penetration of 3 to 4 centimeters. In order to treat deep seated tumors, a craniotomy is
performed to remove the scalp and skull. Even with the craniotomy the treatment lasts
from 1 to 6 hours. To overcome this limitation, current BNCT research is directed at
filtering out fast neutrons, thermal neutrons, and photons to produce an epithermal
neutron beam with an energy range of 0.5 eV to 10 keY. An epithermal neutron beam
passes through the skin and skull and moderates to thermal energy levels around 2 cm into
the brain, allowing the treatment of tumors deeper than 4 cm without surgery. With an
epithermal fluence of lxl09 nfcm2 sec· i , the treatment period is reduced to under one
hour.

8

At present, there are two groups in the United States using the epithermal neutron
beam approach to treat patients on an experimental basis. In 1994 the Brookhaven
Medical Research Reactor, as shown in Figure 2.2, received approval from the Food and
Drug Adminjstration (FDA) to treat 28 patients dying of GBM. In 1995 MIT began
clinical BNCT trials, and the University of Missouri is conducting animal tests?7 It is
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expected that the FDA will give final approval for BNCT to be used as a clinical treatment
within the next two years. 32

A - Reactor Core
B - Beam Shutter
C - Epithermal Filter
Figure 2.2 The Brookhaven Medical Research Reactor
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Chapter 3
Site Selection
3.1 Neutron Sources

An epithennal neutron fluence rate greater than 1 x 109 neutrons cm-2 sec· l is
needed for successful boron neutron capture therapy. At the present time, only nuclear
reactors are capable of generating such beams. There are approximately 35 research
reactors, with power levels greater than 1 MW, in the United States that could potentially
be modified for boron neutron capture therapy. The Brookhaven Medical Research
Reactor, the MIT Research Reactor, and the Georgia Institute of Technology Research
Reactor have irradiation facilities that were designed for medical and biological research.
One alternative source for the epithermal neutrons needed for boron neutron
capture therapy is the spontaneously fissioning isotope californium-252. 252Cfhas a halflife of2.645 years and decays by spontaneous fission 3.09 percent of the time. 252Cfhas a
prompt neutron emission rate of2.31xlOl2 (neutrons sec- l g-l). The entire supply of 252Cf
for the western world comes from the High Flux Isotope Reactor (HFIR) at the Oak
Ridge National Laboratory, which produces less than a gram a year. Over a gram of 252Cf
is needed to produce an epithermal beam of neutrons of sufficient strength, thus making
this option economically impossible.

39

Epithermal neutrons for BNCT can also be produced in low energy proton
accelerators. The main advantages of accelerator-based designs are a low mean neutron
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energy from the

source~

low gamma ray contamination of the beam, low cost, ease of

siting in or near hospita1s~ and a compact geometry. A neutron fluence rate of 1x 109
neutrons cm-2 sec- l can be obtained from a thick natural lithium target under bombardment
by a 2.8 MeV proton beam operating at 10 rnA. The high power density deposited in the
lithium target by a such a beam would melt the lithium metal, even with the most efficient
of forced water cooling systems. Although liquid lithium targets have been used
experimentally, having liquid lithium and water in close proximity to the patient's head
could present a serious problem should one of the cooling lines rupture. Until an advanced
neutron target is developed, this method is not a feasible neutron source ofBNCT.

3.2 Possible Reactor Sites in the United States22
Even if a nuclear reactor has a desirable neutron

spectru~

it is usually not feasible

for BNCT. Most reactors are contained inside pressure vessels surrounded by shielding.
Some reactors are located in containment buildings or underwater in pools. In order to get
an epithermal beam of 1x 109 neutrons cm-2 sec- 1 the patient must be located close to the
reactor, because the fluence rate decreases by approximately {2. For most situations it is
not possible to place a clinical facility inside a nuclear facility.
Extensive work has been done on the conceptual design of clinical facilities for
BNCT at the Power Burst Facility (PBF) at the Idaho National Engineering Laboratory~
the Missouri University Research Reactor (MURR), and the Georgia Institute of
Technology Research Reactor (GTRR). Each of these facilities have outstanding neutron
beam strength and purity, but each facility has its drawbacks. All three of these facility
13

share one common shortcoming: they are research facilities. The GIRR and MURR are
university reactors that are primarily used for scientific research. If they are used for
BNCT~ other research projects will be conducted in the same area. Support facilities will
be minimal and patients will be under external medical supervision. The PBF could
function exclusively as a BNCT

center~

but at a price. In order to build a treatment roo~

a hot-cell needs to be decontaminated and a hole needs to be drilled in the reactor's
pressure vessel. 13 The estimated cost for the conversion of the PBF is at least 30 million.

3.3 Possible Reactors Sites at ORNL22
Another possible location for a BNCT center is the Oak Ridge National
Laboratory. ORNL has six potential epithermal neutron sources: the High Flux Isotope
Reactor, the Oak Ridge Linear Accelerator, the Oak Ridge Research Reactor, the Bulk
Shielding Reactor, the Health Physics Research Reactor, and the Tower Shielding
Reactor.

Unfortunately~

only one of these reactors can be used for boron neutron capture

therapy.
The High Flux Isotope Reactor is a versatile 100 MW reactor that has the highest
thermal flux (2.5xl0 1S neutrons cm-2 sec-I) in the world. The HFIR is used for medical and
industrial isotope productio~ neutron scattering research, materials research,
transplutonium isotope production, material irradiation, and neutron activation analyses.
The HFIR currently has three tangential and one centerline beam tube from which to pull
off neutrons. The best beam for BNCT would come from the centerline tube~ but the flux
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at the end of the epithermal filter, lxl08 neutrons cm-2 sec-\ would be an order of
magnitude lower than what is required.
The Oak Ridge Linear Accelerator (ORELA) has a total neutron production rate
ofO.8xlO I4 neutrons sec-1 at 50 kW. It has 18 flight stations positioned at 9, 20, 35,40,

40, and 200 meters from the target. The flux at the closest target, Ixl07 neutrons cm~2
sec-t, is two orders of magnitude lower than what is needed for BNCT. 1,21
The Oak Ridge Research Reactor (ORR), the Bulk Shielding Reactor (BSR), and
the Health Physics Research Reactor (HPRR) have all been shut down. The cost to restart
one of these facilities and modify it for use in BNCT precludes there use.
The Tower Shielding Reactor, shown in Figure 3.1, can easily be restarted and
modified for use in BNCT?O At present, the 1 MW Tower Shielding Reactor (TSR) is
placed in a concrete shield on an unenclosed 30 meter long by 60 meter wide concrete
pad. Because there is no building around the reactor, a nuclear and medical facility could
easily be built on site around the existing structures. This one of a kind spherical core has
a total neutron leakage of 1.2xl0 15 neutrons sec-I. By adding a filter, an epithermal beam
with a fluence rate of over 1xl 09 neutrons cm-2 sec- I is produced, allowing treatment times
of less than 30 nunutes. The reactor, location, and facility layout make it ideal for BNCT.
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Figure 3.1 The Tower Shielding Facility

3.4 The Tower Shielding Facility42
The Tower Shielding Facility at ORNL was built in 1954 for shielding studies
needed for the Aircraft Nuclear Propulsion Project (ANP). This research project required
that the reactor radiation source be located in a region free from ground or structural
scattering. After the ANP Project was canceled in the early 1960" s, the facility was used to
conduct a variety of experiments, including Space Nuclear Auxiliary Power, nuclear
weapons shield studies, civil defense studies, the Liquid Metal Cooled Reactor (LMR)
16

program, the Gas Cooled Fast Reactor (GCFR) program, and for the conduction of large
scale radiation transport studies.
The TSF consists of four 96 meter high towers erected on the corners of a 30
meter wide by 60 meter long rectangle. Two of the towers were originally used for
suspending the reactor, while the other two were used for supporting other equipment
such as shield components and detectors. In 1975, the reactor was placed in a groundbased concrete shield with a horizontal collimator, including a 80 cm diameter stepped
cylindrical beam port. The shield and collimator were designed to allow placement of
experimental mockups within 91 cm of the center of the reactor and to provide a relatively
uniform spatial profile of the neutron source emerging from the beam collimator.
The reactor collimator opened onto a concrete pad 20 meters wide by 60 meters
long. The radiation from fission and activation products in the core was attenuated by a
large movable lead shutter. The shutter was opened only when all personnel were in an
underground bunker which is covered with 107 cm of dirt and 46 em of concrete.
The original Tower Shielding Reactor (TSR-I) was a boxed shaped 500 kW
reactor. It was replaced in 1960 with the spherically symmetric TSR-II, which has been
operated at power levels of up to 100 kW at both ground level and elevated positions. The
TSF-II core consists of 60 mm thick curved aluminum-clad uranium-aluminum alloy plates
cooled and moderated with light water. The plates are shaped so that the assembled core
is a spherical fuel annulus from which radiation is emitted symmetrically. The neutronabsorbing control plates for the reactor are contained in the fuel-free region centered
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inside the fuel annulus. Outside the fuel annulus is a reflector region that can be filled vvith
aluminum-water, lead-boral-aluminum, or any other combination of material needed.

3.5 TSR Core Region 19
The fuel annulus, the control ball, and the reflector are contained in the lower
section of a cylindrical aluminum tank vvith a hemispherical bottom, as shown in Figure
3.2. This aluminum tank is 244 cm long, has an inside diameter of 94 cm at the
hemispherical end, and an inside radius of 102 cm at the open end to allow maintenance
procedures. The core consists of twenty-one fuel elements designed so that the fuel plates
in adj acent elements join to form many concentric cylinders separated by water passages.
The spherical annulus is 14 cm thick and has an outside diameter of 74 cm. Each fuel plate
is 0.15 cm thick and consists of uranium-aluminum alloy clad in aluminum. The fuel plates
are welded 0.30 cm apart into aluminum side plates to form fuel elements. Three types of
elements are used: annular elements that form a cylindrical fuel annulus; central elements
that are used in the upper and lower sections of the core; and one 7.62 cm diameter
cylindrical plug element, which is centered in the lower central elements. There are 12
annular elements and 8 central elements in the reactor core.
The internal reflector region is filled by a 43.18 cm diameter sphere which contains
six neutron absorbing control plates and the mechanism for positioning them to operate
and shut down the reactor. The assembled control ball is mounted on four blocks which
are welded on the inside of the central cylinder. Each control plate is a dished,
hermetically-sealed hollow plate of 1.59 mm thick stainless steel filled vvith boron carbide.
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Five shim safety plates move simultaneously relative to the fuel to operate the reactor.
Each plate is independently driven toward the fuel, four outward and one downward, to
shut down the reactor. The sixth regulating plate moves vertically in the upper region of
the sphere and can be servo-operated to maintain the reactor power at a constant level. All
cavities within the control ball are filled with water. Movement of the control plates is
achieved by a combination of mechanical and hydraulic forces. As the control plates are
pushed away from the fuel, a shutdown spring is loaded. In the case of an emergency
shutdown, the shutdown spring will fully extend the control plates.

3.6 Core Heat Transfer 19
The reactor was designed so that the surface temperature of the fuel plates is
maintained below the saturation temperature of water at every point in the core. The
saturation temperature in the core is 139.4 C at a pressure of 0.251 .MPa. Under normal
operating conditions, the cooling water flow rate is approximately three m3 min-} and the
maximum allowable power is 1 MW. If the power level were raised to 3 MW and the
cooling water flow rate was dropped to 1.5 m3 min-}, the maximum fuel temperature
wou1d be 96 C, which is below the boiling point even at atmospherics pressure.
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3.7 Site Location and Regional Support42
The Tower Shielding Facility is located approximately 9 miles from the city of Oak
Ridge~

Tennessee and 21 miles from the city ofKnoxville, Tennessee. The site is located

on the edge of ORNL and is easily accessible from Interstate-40. The TSF is easily
accessible for the Southern, Northeastern, and Midwestern States.
Besides ORNL, a BNCT facility at the Tower Shielding Facility has enonnous
regional support. The Tennessee Center for Research and Development (TCRD) has
shown an consistent interest in developing a clinical facility. Due to TCRD's efforts~ the
Department of Energy (DOE) has agreed to lease the TSF for up 99 years to interested
parties.
The University of Tennessee, Knoxville can support all aspects ofBNCT
development and Treatment. Dr. George Kabalka from the Department of Chemistry is
one of the countries leading authorities on boron chemistry and is currently active in the
development of BP A and other advanced boron compounds. The University of Tennessee
Medical Center and Cancer Clinic can provide medical therapies~ radiological oncology~
surgical procedures~ pharmacological research, and patient diagnosis. The University of
Tennessee also has one of two magnetic resonance imagining (MRI) machines in the
country capable of imaging boron instead of hydrogen. Additional support can be
provided by the Department of Veterinary Medicine for animal testing and by the
Department of Nuclear Engineering for nuclear research.
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Chapter 4
Beam Shutter Mechanism

In order to maximize the epithermal fluence rate to the patient during treatment,
and minimize the total dose rate between treatments, a shutter mechanism is needed to
turn the beam on and off The shutter mechanism has passive safety features and the
capability to interchange beam filters. The main limitations imposed on this design are the
allowable dimensions, safety, availability of equipment, and cost of equipment.

4.1 Description of System and Operation
In previous experiments at the Tower Shielding Reactor the Large Concrete Beam
Collimator (LCBC) acted as a horizontal shutter and collimator as shown in Figure 4.1.42
Although the LCBC attenuates decay radiation from fission products and activated
materials, it does very little when the beam is activated. By removing the LCBC, patients
can be positioned 38.73 cm closer to the core of the reactor, producing a fluence rate
increase of approximately 300 percent.
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Figure 4.1 Existing Collimator/Shutter Confi~'1Iration

In order to keep the patient as close to the reactor as possible, the shutter and filter
should be attached and move together. Because the distance to the patient must be
minimized, the shutter/filter assembly can only move horizontally or vertically, as shown in
Figure 4.2. The horizontal configuration allows easy overhead access to both the shutter

i

Horizontal

Vertical

Figure 4. 2 Shutter/Collimator Movement
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and the filter, but it is difficult to move. In the vertical configuration it is difficult to
change the beam filter, but the system has gravity as an inherent safety feature.

Figure 4.3 Shutter in the closed position

In order to get a fast, effective, and safe shutter/filter syste~ the best option is the
vertical configuration hydraulically lifted with the shutter stacked atop the filter. The
assembly would remain in the lowered position with the shutter in front of the reactor
beam portal until the time for therapy to begin, as shown in Figure 4.3. At the beginning of
the therapy the hydraulic system will activate and the filter and collimator will be lifted
into the position between the reactor beam portal and the patient, as shown in Figure 4.4.
At the end of the treatment session the hydraulics win lower and the shutter will again
cover the beam portal, making the treatment room safe for facility workers to enter while
the reactor is operating.
24
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Figure4.4 Open shutter configuration

4.2 Interchangeable Filter Design
In order to maximize revenues, the BNCT Tower Shielding Facility can also treat
melanoma, lung, colon, prostate;. and breast cancer. Each type of cancer requires a unique
filter and collimator, and this design has the capability to change the filter/collimator
assembly with ease. A cross bar installed at the shutter rest position is capable of holding
the shutter section of the assembly in place without the spectrum modifier in position. This
allows the further lowering of the filter/collimator assembly clear of the cross bars. At this
level the filter/collimator can be removed from either side and replaced with a different
type of spectrum modifier and collimator.
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4.3 Safety Features
The primary concern in this design choice is safety. This design employs an innate
gravity safety feature; in the event of an accident where the hydraulics would fail, the
assembly will fall into the closed position and end any radiation exposure to the patient.
The shutter section of the assembly has been designed to be 50 cm wider than the
spectrum modifier section of the assembly. Within this additional space there will be two
dual purpose cross bars located at the base of the shutter when it is in the lowered
position. These bars would provide a resting place and emergency support for the shutter
should there be any reason that the spectrum modifier or hydraulics failed to support it. A
series of guide bars are also placed along the side edges of the walls, beginning at the
cross bar and extending to the top of the shutter in the raised position. These are to insure
that the assembly does not move from its intended vertical course and that it cannot be
inadvertently or accidentally removed from the beam portal opening. An additional
hydraulic power unit, reservoir, and pump are included in the confinement building for
system redundancy.

4.4 Hydraulic System Specifics7
The hydraulic lifting system for the filter/collimator assembly, shown in Figure 4.5,
is required to raise approximately 11,000 kg 2.5 meters. For safety and future
expandability of the facility, the lifted mass was rounded up to 18,000 kg. This height was
determined from the maximum distance that the assembly will need to be raised plus an
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additional amount for changing the filters. A vertical lifting force twice the weight of the

Shutter

Filter

Figure 4.5 Hydraulic System

obj ect being lifted is needed for fast operation. The hydraulic system required for this
application consists of four separate five inch bore cylinders, each with a two inch
diameter rod., capable of lifting over 37,000 kg. A cylinder is placed at each comer of a
] 10 cm wide by 72 em long plenum on which the filter and shutter will rest. For added
safety, an additional cylinder of identical dimensions is located at the center of the plenum
so in the event that one of the exterior cylinders should fail, the assembly can be safely
guided to the closed position. Each of the cylinders operate at 8.69 MPa delivering over
9,350 kg of force, which will more than adequately cover any future need of the facility.
The cylinders can be obtained at an estimated cost of approximately $4,870 each. In
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addition to the cylinders, a hydraulic power unit with a 114 liter reservoir and pump will
be required. The estimated cost for the pump and reservoir is $3,500, and the
miscellaneous tubing and fittings required to complete the system are an additional $750.
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Chapter 5
Shutter Design

The beginning of the shutter assembly is located 53.66 cm from the center of the
reactor. The combined neutron and gamma dose rate at this point is approximately 3 x I 0

5

Sv hOU{l. The recommended annual limit for radiation workers is 50 mSv yr-l.38 In order
to reduce the dose rate to acceptable levels, a shutter 110 cm thick must be constructed to
attenuate the beam. The shutter must protect both the patient and the facility staff from
unnecessary radiation exposures. The primary limitations imposed on the design are the
allowable dimensions, mass, safety limits, cost, and feasibility of manufacture.
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5.1 Shutter Calculations

The shutter calculations were performed using XSDRNPM (X-Section Dynamics
for Reactor Nucleonics with Petrie Modifications) running on a Sun SPARC server lOOOE
with a 84 group P 5 cross-sections library and external source provided by ORNL. A
program, called DOSE, was written to easily display the :fluence and dose rates at the last
spatial mesh point. 33
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5.2 Detailed Description of Shutter Design
In order to maximize the number of patients treated per day and to minimize
operational stress on the reactor and control ball, the facility will operate at during
treatment and 100 kW between treatments. A beam shutter is used to reduce the radiation
levels in the treatment room to as low as reasonably achievable when the reactor is
operated at 100 kW.
Approximately 84 different shielding models of varying thickness and composition
were considered. Water and concrete are poor shields for this application, as shown in
Table 5.1. The water shield thermalizes neutrons, but allows a large number of gamma
rays to pass through uncollided. The concrete shield blocks the gamma rays, but allows
the fast neutrons to pass through. A mixture of borated polyethylene and tungsten provide
the best shield for the limited space. The borated polyethylene has a high hydrogen
content, allowing it to thermalize the fast neutrons, while the tungsten provides gamma ray
shielding.

Table 5.1 Shutter Calculations
Shielding Configuration
110cm Water
110em High Density Concrete (HD)
aDem HD, 20cm Water, 1cm Cd, gem Pb
1Oem W, 72cm B-Poly, 18cm B\, 1Oem Li-Poly
15em Bi, 68em B-Poly, 13cm W, 14em B-Poly
1Oem W, 15cm B-Poly, 5em W, 50cm B-Poly, 1Oem W,
20em B-Poly
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Dose (Sv/hr)
176
6.64
1.71 E-02
B.16E-03
3.68E-03
1.70E-03

The final shutter design, shown in Figure 5. 1, reduces the dose rate at 1 MW
operating power to 1. 70x] 0-3 Sv hr-] on the wan closest to the reactor. When the reactor
power is lowered to ]00 kW, the dose rate drops to 1.07xlO-5 Sv hr- 1, which is an
acceptable limit with an occupancy factor of 4 hours per week
Tungsten

B-Poly

Figure 5.1 Final Sbutter Design
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Chapter 6
Collimator Design
The major criterion that one must consider when designing a collimator for use in
boron neutron capture therapy is to deliver the highest possible thermal fluence to the
brain, while administering the lowest achievable whole body dose. The spectrum of the
beam is modified to the optimal spectrum for boron neutron capture therapy by a filter
designed by engineers at ORNL. Other limitations imposed on the design the allowable
dimensions, mass, safety limits, cost, and feasibility of manufacture.

6.1 Collimator Modeling and Calculations 43
The two dimensional discrete ordinance program DORT is ideally suited for
collimator and shielding design because it generates the exact fluence rate for each mesh
point. An 84 group cross sections with P j scattering and a combined gamma ray and
neutron source were provided by ORNL. All DORT calculations are performed on four
Sun SPARCstation 20's, one SPARCserver 690, and one SPARCserver 1000E using P s
scattering, a S-16 quadrature, 84 group cross sections, and the supplied reactor source.
Although most calculations were finished in under an hour, DORT requires a large amount
of disk space to store the output files and special programs to read them~
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6.2 Programs to Analyze DORT Outpue 3,29
Two programs were written to analyze the flux output from DORT. The first
program, called FLIP (Elux Linear Interpolation :erogram), takes the boundary source
provided by ORNL26 and interpolates it to the intervals needed for the collimator
geometry. This is necessary because ORNL's filter model has different intervals than
what is needed for the design of the collimator. FLIP reads the intervals from an input file
called READFLUX.INP, which contains ORNL's original intervals and the new
collimator intervals.
The second program, called DRIP (DORT Reading Interpolation ~rogram), reads
the flux output from DORT. DRIP displays the fluence and dose rate for each energy
group at points specified in an input file. The dose rate is calculated by multiplying the
energy dependent 1991 ANSI standard dose response function, VELM61.DRF, by each
energy group. The fluence and dose rates are displayed in a table and a Postscript flux
map of the output is displayed.
A test was performed before running any calculations to verifY that the source
created with FLIP was the same as ORNL's. The fluence rate calculated with the modified
source was compared to a sample problem supplied by ORNL at two points: 0,0 and 50,0.
Both points were in close agreement, as shown in Figure 6.1 and 6.2.
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6.3 Collimator Optimization 41
Three points of interest are used to determine the optimal col1imator design. The
first point is along the centerline of the reactor at the col1imator exit where the epithermal
9

neutron fluence should be the highest. The second point is 7 cm into the brain where a
high thermal fluence is needed. The third point is 50 cm to the right of the center of the
bra.in where the total fluence rate should be low. This point is of importance because
limiting the whole body dose is a major design restriction.
The first mesh used to model the filter and coHimator consisted of approximately
13,000 one cm by one cm mesh points. In order to cut down the CPU time for each
calculation, a course mesh of approximately 5,700 points was used instead of the fine
mesh. A comparison of the fine mesh to the course mesh at the collimator exit is shown in
Figure 6.3, and for 7 cm into the brain in Figure 6.4. Because the flux distributions are
similar, the course mesh can be used to reduce runtime from 8 hours to under one hour.
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7 em Into the Brain

In collimator design five properties are varied in order to achieve the optimal
thermal neutron fluence and penetration into the brain. These properties include the
collimator material, the radius of the opening, the angle of the collimator, the thickness of
the collimator, and the overall position of the collimator, as shown in Figure 1.2 (page
3). Eighty-nine different collimator models were created and analyzed by varying these

parameters.

36

I

Materials used in a collimator should rapidly moderate~ absorb, and/or scatter
neutrons so that the majority of neutrons reaching the patient are coming through the
collimator opening. Lithiated polyethylene, lithiated paraffin, and borated polyethylene are
good moderators because of their high hydrogen content. Lithium and boron have high
absorption cross sections for thermal neutrons and decay by alpha emission. Out of five
collimators made of Iithiated

polyethylene~

lithiated

paraffi~

borated polyethylene,

concrete, and aluminum, the lithiated polyethylene and aluminum collimators have the
highest epithermal fluence rates. A comparison of the models at the collimator exit shows
that the aluminum has a clear advantage over the lithiated polyethylene~ as shown in
Figure 6.5. A comparison of the two models seven cm into the brain shows that the
aluminum has approximately two times the fluence rate of the lithiated polyethylene, as
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shown in Figure 6.6. Unfortunately, aluminum has a high epithermal and thermal fluence
rate because it is a poor collimator. The neutrons that pass through the aluminum lose
very little energy when compared to the lithiated polyethylene, as shown in Figure 6.7. In
order to nunimize the dose to the patient's body and maximize the epithermal fluence,
lithiated polyethylene is used as the collimator material.
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The radius of the collimator opening determines the size of the epithermal beam
used during treatment. For the treatment of deep seated brain tumors, like GBM, a wide
38

collimated epithermal beam works better than a narrow col1imated beam . Two models
with a 6 cm and 9 cm radius are compared at the collimator exit in Figure 6.8. In order to
maximize penetration, as shown in Figure 6.9 by the higher fluence rate~ a 9 cm radius is

used for the collimator opening.

~

~

«1-.

B.OOE+08

CD <

6.00E+08

.cor....,..J fIJ
....,N
.-

I

c: <

:::tE

-r------------,
--Scm
--9cm

4.00E+08

...
u
CD • 2.00E+08
Q.c:

)(-

::J

O. OOE+OO

u::

-ffH.IHl+H+H+fft#+!oto!H+H+fm#mH1HH+Hf#l..Hl~~~HH
~

a

m

~

00

ID

~

~

~

N

~~NM~I.!)IDr.....oo

Energy Group
Figure 6.8 Radius Changes at Collimator Exit

~

...., <

"2

5

=: c:: ;:e- ~ ~
_ ca
CD-I
:::s

....

LL

:S
CD
~

1.50E+OB , - - - - - - - - - - - - - - - n

F6~
~--9cm

1. ODE+08
5.00E+07

O. OOE+oO -tt+tttH+H+H-H+++!+H+I+H++++++++r+++++H++H++F#"m~
~
00 ~ N
m ~ M a ~
~
N N ('I') ~ to I.!)
Energy Group
Figure 6.9 Radius Changes 7 em Into Brain

39

By decreasing the angJe of the collimator, the attenuation provided by the lithiated
polyethylene is reduced. Although this allows more epithermal neutrons to pass
uncollided, there is an associated increase in fast neutrons and gamma rays, as shown in
Figure 6.10. The negative effects of the fast neutrons and gamma rays is outweighed by
the positive effects from increased penetration provided by the eleven degree collimator~
as shown in Figure 6.11.
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- - 45 Degrees

---- ro Degrees

Varying the thickness of the collimator has approximately the same effect as
changing the collimator angle. By decreasing the thickness, more epithermal neutrons can
pass through the collimator uncollided, as shown in Figure 6.12. Changing the thickness
of the collimator does not drastical1y change the penetration. The real disadvantage of thin
collimators is that they provide little protection to the patient's body, as shown in Figure
6.13. For this reason, a 10 cm thick collimator is used to reduce beam contaminates

produced from lowering the collimator angle.
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The overall positioning of the collimator with respect to the last layer of bismuth
in the filter was examined. By placing the collimator inside the bismuth layer, the air gap is
removed and the patient is moved closer to the reactor. A model with the coJlimator
placed entirely in the bismuth layer with no air gap, a model with 5 cm of the collimator
placed in the bismuth, and a model with the collimator in the normal position are
compared. Even with the patient closer to the reactor, the standard collimator has a higher
epithermal fluence rate at the collimator exit, as shown in Figure 6.14. Placing the
collimator inside the bismuth not only lowers penetration but increases the gamma ray
dose delivered to the patient's body, as shown in Figure 6.15. The geometry that
optimizes the flux to the brain while minimizing the dose to the patienCs body is the
standard configuration.
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6.4 Detailed Collimator Design
In order to decrease the amount of filter material used and increase the epithermal
fluence rate at the collimator exit, the filter/collimator assembly is cylindrically shaped,
wrapped in a reflector, and fits directly over the reactor beam port. Beryllium, lead,
43

tungsten, aluminum, and graphite were tested as reflectors. The test results are as shown

in Table 6.1.

Table 6.1 Reflector Changes

MateriaJ

Epithermal
Fluence Rate

Aluminum
Lead
Tungsten
Graphite
Beryllium
In order to maximize the epithermal fluence

3.44E+09
4.89E+09
3.04E+09
1.32E+09
3.07E+09
rate~

lead is used as the reflector even though

it also increases the fast neutron fluence rate.
The final design is a 10 em thick lithiated polyethylene collimator with a 9cm
radius and an 11 degree angle. The collimator is attached to the filter and wrapped in lead
as shown in FibJUre 6.16. The total neutron and gamma ray fluence rate across the outside
surface of the final collimator is shown in Figure 6.17. The fluence rate decreases at an
acceptable rate across the collimator~ but some neutron Jeakage is still coming from the
reflector and air gap. The thennal and epithermal neutron fluence from the exit of the
collimator and through the phantom is shown in Figure 6.18. The thermal fluence rate
peaks at approximately three centimeters into the brain, approximately five centimeters
from the collimator, and then slowly decreases. With this thennal distribution, any tumor
located in the head can be treated.
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Figure 6.16 Final Collimator/Filter Design
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Chapter 7
Clinical Facility Design
7.1 Site Location42
The Tower Shielding Facility is located on a hin with an elevation of 1069 ft 2.35
miles south-southeast of Oak Ridge National Laboratory (ORNL). It is 9 miles from the
city of Oak Ridge, Tennessee and 21 miles from the city of Knoxville, Tennessee. The
immediate terrain on all sides of the tower structure slopes downward at the base of the
towers, and the grade gradually rises to the top of Copper Ridge, approximately 400 ft to
the north of the towers.

7.2 Present Tower and Facility Layout

42

Since the TSR-It is currently classified as an unshielded reactor, the TSF is
situated within a general exclusion area that is enclosed by a 6-ft-high chain-link fence
topped with three strands of barbed wire.
Two reinforced-concrete underground buildings are located adjacent to and north
of the towers, as shown in Figure 7. 1. The smaller building is used as a service and shop
area and is connected to the larger building by an 2.44 meter wide walkway. The larger
building contains the reactor controls, data-collecting facility, counting room, and offices.
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The buildings are shielded against radiation by an 0.46 meter thick concrete roof covered
with approximately one meter of dirt.

o
Maintenance

Room

Offices

--f--.... Ramp Leading
out to Facility

Offices

Reactor Control
Room

Figure 7.1. Uodergrouod Bunker

The tower structure is a braced and guyed steel frame forming a 30 meter by 61
meter rectangle> with a leg placed at each of the four comers. Each leg is 2.75 meters
square, 96 meters high, and terminates at the lower end in an inverted truncated pyramid.
Each pair of legs is joined at the top by a horizontal truss-type bridge running east and
west. Maintenance access is provided by a bridge between legs I and IV of the north
tower.
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The tower structure is protected from lightning by means of a wire grounding net.
A copper-clad steel-strand shielding wire is mounted on porcelain insulators to form a
rectangle at a 5-ft minimum above the entire structure. Shielding wire also extends from
the top of each tower to the ground to protect the inclined guys. The steel towers, the
inclined guy wires, and the grounding system are connected to a buried counterpoise. The
resistance to the ground of the above-ground grid system is between 1 and 3 ohms.
A two-section reinforced concrete pool provides shielding during the removal and
storage of fuel elements. The pool is located midway between the west tower legs; its
large section is 6.10 meters square and 7.62 meters deep. The small section of the pool is
1.22 meters wide, 3.66 meters long, and 6.71 meters deep. A guided float is installed in
the pool for raising and lowering reactor shields. The water in the pool is circulated
through a system of filters to keep it clear for raising the shields.

7.3 Proposed Additions
An outpatient medical facility, estimated to cost between 1.8 and 2 million dollars,

will be constructed at the reactor site to house the necessary equipment for the boron
neutron capture therapy, as shown in Figures 7.2 and 7.3.
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A confinement building, 30.48 meters long and 15.24 meters wide, with 0.45 meter
thick concrete walls, is added around the reactor and pool to insure that exposure is
limited to very low doses and all radioactivity is contained. A 9.14 meter long and 4.57
meter wide loading area is located in the northwest corner of the confinement building.
The treatment room is 15.24 meters wide and 15.24 meters long to reduce neutron
backscatter. It is located immediately adjacent to the east side of the reactor, adjoining the
confinement building at the reactor porthole. The treatment room will have 0.45 meter
thick concrete walls with IS cm borated polyethylene tiles to absorb any backscatter
radiation from the neutron beam. The dose rates outside of treatment room are shown in
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Figure 7.4. On the south side of the treatment room wiH be an observation room, 6.10
meters long and 3.66 meters wide, that will allow medical personnel and the patient's
family to observe the treatment.

8* 10-6Sv /hr

t
3*10-6 Sv/hr

4*10-6 Sv/hr
7* 10-7 Sv/hr
Figure 7.4 Doses Outside Treatment Room

Should an emergency in the treatment procedure arise, an emergency room, 6.10
meters long and 7.62 meters wide, will be located on the south side of the treatment room
so that the patient may be taken directly from the treatment room to the emergency room.
The primary emergency room equipment can be purchased for approximately $30,000. If
a medical enlergency occurs while the patient is in the treatment room, a surgical scrub
room, 3.04 meters wide and 3.04 meters long, will be accessible to the emergency room
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so that physicians may properly prepare for surgery. The cost estimates for the surgical
scrub room equipment are $]0,000.
A maintenance room, with dimensions of 6.10 meters long and 6.10 nleters wide,
will be added for eJectricaJ and mechanical support. The facility has two storage areas: one
on the north side of the treatment room, connected to the maintenance room, and the
other adjacent to the observation room on the south side of the treatment room. A faculty
lounge, 6.10 meters long and 3.51 meters wide, is located north of the maintenance room.
Six offices for physicians and technicians will be in the northwest comer of the facility,
along with a conference room. 23

7.4 Optional Thermal Treatment Room
An additional treatment room can be added into the existing facility with minor
modifications to reactor and shutter assembly. Neutron leakage from the primary filter is
directed through a tank of heavy water, which moderates the fast and epithermal neutrons.
With 30 cm of heavy water place 97 cm from the beam centerline, as shown in Figure 7.5.
The thermal neutron fluence at the exit of the heavy water filter is 1.95x 109 .
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Figure 7.5 SL"Condary Treatment Room

7.5 Treatment Sequence
Upon arrival at the facility, the patient and his or her family enters a 12.34 meter
long by 6.25 meter wide waiting room at the main entrance on the west side of the
building. The patient then registers at the reception area. Restrooms are accessible from
the waiting room adjacent to the reception area. The physician then directs the patient and
family from the waiting room to an exam room. There are eight examination rooms;> 3.05
meters wide and 6.10 meters long, located south of the emergency room. Each
examination room is estimated to cost $9;>000. The total price for all examination rooms is
approximately $80,000, which includes a nurse call system. A technician or nurse
prepares the patient for treatment, and takes any final measurements for dose calculations.
These calculations are determined on computers, estimated at $70,000 each, which are
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housed in the pretreatment planning room located on the southeast comer of the facility.
A chemistry laboratory, 6.10 meters square, and a pharmaceutical laboratory, 6.10 meters
long and 3.66 meters wide,. is located west of the examination rooms and are used to
quickly transfer and administer the boron pharmaceutical to the patient. After the patient
has received the boron compound, he or she is transferred to the treatment room. The
.family can then move to the observation room or back to the waiting room. After the
treatment has been completed, the patient is returned to the examination room for posttreatment observation.

7.6 Filtration System45
The confinement building and the treatment room have separate air filtering and
ventilation systems from the rest of the facility to contain radioactive particles in the event
of an emergency. To maintain the facility the two rooms have individual vacuum control
systems but can share a common filtration system. Each of the vacuum control systems
include two redundant fans, a differential pressure sensor, motor operated dampers, and
control circuitry. Due to the need to combine the ductwork to the filtering system, the
treatment room is kept at a higher pressure. If there are any leaks, or if the system should
fail, the net leakage of material is directed into the confinement building and not the
treatment room. The air filtration system for the confinement building and the treatment
room consists of a filter unit, a centrifugal fan, and an air flow control module. The filter
unit contains a demister, a relative humidity heater, a prefilter bank, HEPA filter bank, two
banks of carbon absorbers in series, and another HEP A filter bank. The air flow control
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unit contains a differential pressure sensor and transmitter, control circuitry, a damper
actuator and two modulating dampers. The vents from this system are equipped with
radiation monitoring equipment. This system creates the need to limit the recirculation of
the air to the confinement building. The monitored vents in the treatment room can also
act a removal system in case of an accident involving leakage of material into the
treatment room and additional facility areas. This system is the mirror image of the type
currently used in power producing nuclear plants, and is more than adequate to meet
requirements.

7.7 Reactor Coolant System35 ,42
The existing reactor coolant system consists of a main pump that pumps
demineralized water from the detention tank through an aluminum pipe into the reactor.
The hot leg coming out of the reactor then goes to forced draft air radiator. In order to
obtain a Class 104 license from the Nuclear Regulatory Commission, this system needs a
substantial upgrade.
A flow header is placed on top the pressure vessel to provide three separate
coolant loops. Each coolant loop has its own heat exchanger, with 5 m 2 of surface area,
and a 7,500 W pumping system. Each added loop costs approximately $20,000. The
forced air radiator is replaced with a cooling tower approximately 6 meters wide, 12
meters long, and 6 meters high at a cost of $20,000.
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7.8 Future Expansion
The proposed facility is designed for outpatient treatment in order to minimize
startup cost. The facility also has the capability to be expanded for additional inpatient
accommodations when more revenue is desired. Long term patient rooms::> a

cafeteri~

an

X -ray room, an MRI room, a PET scan room, and additional office space ·can be added on
the ground level as well as second and third floors. A research laboratory and facility for
animal testing has also been proposed for research on other treatments::> such as those for
lung, breast::> colon, and prostrate cancer. This facility would be in a separate building
from the treatment center, so that sanitation could be assured for patients. Table 1
summarizes the cost for the facility.
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Chapter 8
Conclusions
In conclusion, the optimally designed collimator yields an epithermal neutron flux
of3.44x 109 neutrons cm-2 see-} at the eollinlator exit, and a thermal neutron flux of
] .58x109 neutrons em -2 see· l at a point 1 cm into the brain. Thus, the 1 MW reactor at
the Tower Shielding Facility can be utilized to generate a more optimal does than that
currently being used at the 5 MW reactor at Brookhaven National Laboratory.
(Epithermal neutron flux of 1.8x109 neutrons cm-2 sec· i )
The conceptually designed shutter lowers the dose to 1.1x 10-3 Sv hr- I at the
shutter's surface when the reactor is operating at full power.
The overall facility conceptual design incorporates all the necessary medical
accommodations in an efficient, outpatient clinic. The treatment room is designed with
0.46 m thick concrete walls with a layer of 15.2 cm of borated polyethylene to minimize
both the dose to adjacent rooms and the backscatter dose to the patient.
The entire conversion process and construction of the facility would cost
approximately $20 million, and could generate approximately $24 million in annual
revenue at an approximate cost of $80,000 per patient.
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Chapter 9
Future Work
There are several design considerations that have not been mentioned thus far.
These will need to be addressed in order for the conceptual design of the BNCT clinical
facility at the Tower Shielding Reactor Site to be complete.
A feasibility study for a third treatment room with major structural changes will
need to be made. Also, the a feasibility study of converting the facility from an out patient
facility to a primary care facility that is self-sufficient needs to be performed. The current
facility design must include paving and additional parking with an economic analysis of
the two. A conceptual development of the second treatment room with a maximized beam
must also be developed.
In the future, one must evaluate the currents, neutron kerma, and kerma at the
collimator exit to generate an intensity vs. purity plot for comparison with ORNL' s
optimum beam.
For the optimum beam and a minimized dose at the shutter exit, codes must
continued to be run. A detailed analysis of the thermal hydraulics must be performed.
Finally, a more detailed economic analysis must be performed for the design to be
complete.
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Appendix 133
Programs
AI.! Dose
real flux(84),drf(84)
cbaracter*20 xsname
character* 120 aline,aprev
print*,' XSDRNPM output file?'
read(*, '(a20Y)xsname
open( 1,file=xsname,fonn='formatted',status='old')
read(l:(aI20)')aline
C*****************************************************************
C

C

print *,aline

C

*
*
*

C*****************************************************************
10 if(aline(3: 12).ne.'total flux')tben
read( 1, '(a120)')aline
C*****************************************************************
C
C
C

print *,aline

*
*
*

C*****************************************************************
go to 10
endif
read( 1, '(aI20)')aline
read( 1, '(a120)')aline
do 30 ibase=O,9
20 if(aline(3 :6).ne.'int.')then
aprev=aline
read( 1,'(a 120)')aline
C*****************************************************************
C

C
C

print *,aline

C*****************************************************************
go to 20
endif
read(aprev, '(7~8n3.0)')(flux(ibase*8+i),i= 1,8)
read( 1, '(a120)')aline
30 continue
40 if(aline(4:6).ne. 'ela')then
aprev=aline
read(1,'(a120)')aline
C*****************************************************************
60

*

*
*

C
C
C

*

print *,aline

*

C*****************************************************************
go to 40
endif
read(aprev, '(7x,8fl3.0)')(flux(i),i=81 ,84)
call daiso('velm61.drr,l, 10000)
call daisr('drf,0,84,drf,l)
vai=O.
do 50 i=I,84
val=va1.+drf(i)*flax(i)
50 contiuue
write(*,9010)
9010 format(/4x,'Grp."5x,'Flux',11x,'DRF',12x,'%'/2x,
*'======= ============ ===','=========== ==:=========:=')
9020 format(4x,i4,2x,lpe12.5,1x,lpeI4.7,Ix,OpnO.4)
do 60 i=I,84
write(*,9020)i,flux(i),drf(i),fiux(i)*drf(i)lval*100.
60 continue
val=val*4.24E4
print*,' The dose rate is ',\lal/ mremlhr'
call pfstop
stop

end
C**********************************************************************
C**********************************************************************
subroutine pfstop
parameter(nscrx= I 0000)
parameter(ncscrx= I 0000)
character* 1 zca
commonlscrchlnscr,za(nscrx),izzz 1,izzzm
commonlcscrchlncscr,zca( ncscfx),izzzcm
ratio 1=(izzzm *1. )/(nscrx* 1.)* I 00.
rati02=(izzzcm*1.)/(ncscrx* 1.)*100.
write(*,9010)izzzm,nscrx,ratiol
used ,ilO,8h out of ,ilO,
9010 format(/l7h EXT
*25h reallintegervariables (,:f8.3,2h%»
write(* ,9020)izzzcm,ncscrx,rati02
9020 format(12x,5h and ,ilO,8h out of ,ilO, 12h characters ,12x,lh(,f8.
*3,2h%)1)
return

end
subroutine daiso(a200,lu,idum)
02/19/94
C**********************************************************************
C

C Module name:
C DAISO
C

C Called modules:
C GTTOKE
C

C External variables - used:
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*

C A20
C LU
C
C Internal variables:
C ALINE
C
C Variables read:
C ALINE

C*(
1*4

C*80

C*80

C
C**********************************************************************
parameter(ntokex= 100000)
character* 32 token
integer*4 toklen
common/tokenfntoke,token(ntokex),toklen (ntokex), irefind
character*(*)a200
character*20 a30,afile(10)
character*80 aline
integer lus(IO)
data lusll ,9 1,92,93,94,95,96,97,98,99/
lus(l)=lu
afJle( 1)=a200
ifile=l
nline=1
10 open(lus(ifile),file=afile(iflle)(I:leng(afile(ifile),20»,
*form='fonnatted',status='old')
C**********************************************************************
C
C Read input and tokenize

C
C**********************************************************************
20 read(lus(ifile):(a80)',end=50)a1ine
if(aline(l :8).eq.'include ')then
do il=9,38
if(aline(il:il).ne.' ')goto 30
enddo
30 j=l
a30=' I
do i2=il,38
if(aline(i2:i2).eq.' I)go to 40
a30(j:j)=a1ine(i2:i2)
j=j+l
enddo
40 ifile=ifile+ 1
if(ifile.gt.l0)then
write(* ,901 0)a30,afilc(ifile-l)
9010 format(/2x, '======================','========================',
*'========'/2x, '=',54x:='l2x, '=',5x, 'DAISY input error!.,3lx,'='1
*2x,'=',54x,'='/2x,'=',5x,'The include of file ',a28,lx,'='/2x,
*'=',5x, 'by file ',a28,13x:='/2x,'=',54x,'='/2x,'=',5x,
*'Exceeds the limit of 10 ','nested includes', lOx, '='/2x, 1=',54x,
*'='/2x,'=',5x,'Halting execution.',31x,'='/2x,'=',54x,'='/2x,
*'=======================1, '=====================',1========')
stop
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endif
afile(ifile)=a30
do j= I, ifile-l
if(afile(ifilc).eq.afile(j»tben
write(* .9020)afile(ifile-1 ),afile(j)
9020 fOl1IIat(/2x, '=======================',1======================1,
*'========'/2x,'=',54x,'='/2x,'=',5x,'DAISY input error!',3Ix,I='1
*2x,'=',54x,'='/2x,'=',5x, 'File ==> ',a28, 12x,'='/2x,'=' ,5x,
*'includes file ',a28,7x,'='/2x,'="54x,'='I2x,'=',5x,
*'whlch is already open' 27y '='/2x '=' 54 y '='/2x '=' 5x,
*IHalting execution. ',3 Ix, '='/2x, '="54x, '='/2x,
*'====================','======================','==:==:==:=:'1
stop
endif
enddo
go to 10
endif
caJl gttoke(aline)
nline=nline+ 1
go to 20
50 close(lus(ifile»
ifile=ifile-l
if(ifilc.ne.O)go to 20
nline=nline-l
irefind=1
C**********************************************************************
C
C TemJX)rary write
C
C**********************************************************************
C write(* ,9030)ntoke
C 9030 formate ntoke ',i5)
C '\\'fite(* ,9040) (i, token(i),i= I ,ntoke)
C 9040 format(5x,i5,a)
return
end
subroutine daisr(atitle,idfalt,nvald,val,ist)
C**********************************************************************
C
C Module name:
C DAISR
.. ,

&'")

"...,

"

C
C Called modules:

C DAISF
C
C COMMON blocks:
C token
C

C Parametcrs(value):
C
C External variables - used:
C ATITLE
C*(
1*4
C IDFALT
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C NTOKE
1*4
C NVALD
1*4
C TOKEN (ntokex)
C*32
C TOKLEN (ntokex)
1*4
C*(
C VAL (*)
C
C External variables - set:
C TOKEN (ntokex)
C*32
C VAL (*)
C*(
C
C IntemaJ variables:
C IT
1*4
C
C Variables read:
C VAL (*)
C*(
C
C Variables written:
C ATI1LE
C*(
]*4
C NVALD
C VAL (*)
C*(
C
C**********************************************************************
panuneter(ntokex=] 000(0)
character* 32 token
integer*4toklen
common/token/ntoke, token{ntokex), toklen(ntokex),irefind
charac1er*(*)atitle
real val{*)
nval=O
if( nvald.1e. O)lhen
return
endif
C**********************************************************************
C
C call daisf{atitie,l,it)
C
C**********************************************************************
call daisf(atitle,ist,it)
if(it.eq.O)then
if{idfalt.eq.l )return
write(* ,9010)atitIe
9010 format{II' DAISRERROR- VARIABLE ',a32,' NOT FOUND')
write(* ,'(//)')
write(99 ,90 10)atitle
write(99 :(//)')
stop
endif
10 if(nval.ge.nvald)then
C**********************************************************************
C
C
This allows the user to put an fE' even if the count is right
C
C**********************************************************************
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if(loken(it).cq.'e')iL=it+ 1
return
endif
if(it.gt.ntoke )then
if(idfalt. eq. 0) then
wrile(* ,9020)atille,nval,nval~(ii,val(ii),ii= l,nval)
write(* :(/1)')
write(99, 9020)atitle,nval,nvald,(ii,val(ii),ii= 1,nval)
write(99,'(/I)')
9020 formate//' DAISR ERROR - ARRAY ',a32f is only given "
* i5,' of the ',is,' entries reqwced:'/(S~i5,2x,lpe15.8»
return
else
return
endif
endif
if(it.ne.ntoke.and.token(il+ 1).eq. '=')lhen
call daisf(atitle,i~it)
if(iLeq.O)then
if(idfalt.eq.O)tllen
wrile(* ,9020)atille,nval,nval~(ii;\lal(ii),ii= l,nval)
write(* ,'(/1)')
wcite(99,9020)atille,nval,nvald,(ii,val(ii),ii=1,nval)
write(99, '(/1)')
return
else
return
endif
endif
endif
C**********************************************************************

C
C Special symbol = r
C
c nrep val repeats value VAL NREP times
C
C**********************************************************************
if(token(it)( 1: 1).eq. 'c')tben
if(toklen(it).eq.l )then
it=it+l
else
token(it)( 1:32)=token(it)(2: 32)
endif
read(token(it),9030)nrep
it=it+l
read(token (it), 9040)rep
do i=l,nrep
nval=nval+ 1
val (nval)=rep
enddo
it=it+l
C**********************************************************************
C
C Special symbol = f
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C

f val

fills rest of field with value VAL

C

C**********************************************************************
elseif(token(it)(] : 1).eq. 'f) then
if(toklen(it).eq.I ) then
it=it+l
else
token(it)(1 :32)=token(it)(2:32)
endif
read(token(it),9040)rep
nrep=nvald-nval
do i=l,nrep
nval=nvaI+ 1
val( nval)=rep
enddo
it=it+l

C**********************************************************************
C

C Special symbol = e
C e Does nol bother rest offield (Allows progrdIIlmer to
C
C

initialize input values to defaults)

C**********************************************************************
elseif(token (it). eq. 'e')then
nval=nvald
it=it+l

C**********************************************************************
C
C Special symbol
C
C

i
vall i nint val2 = Interpolates NINT values between VALl
and VAL2 (results in NINT+2 entries)

C

C**********************************************************************
elseif(token(it)(l: 1).eq.'i')then
if(toklen(it).eq.l )ilien
it=it+l
else
token(it)(l :32)=token(it)(2:32)
endif
read(token(it),9030)nint
it=it+ I
read(token(it), 9040)val2
vall =val(nval)
do i=l,nint
nval=nval+ I
val( nvaI)=vall +(val2 -vall )* i/( nint+ 1.0)
enddo
mlal=nval+ I
val (nvaI)=val 2
it=it+I

C**********************************************************************
C
C Special symbol

1
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C
C

val I I nint vall
Interpolates NINT values between VALl
and VAL2 (results in NINT+2 entries)

C
C**********************************************************************
elscif(token(it).eq. 'l')then
it=it+1
read(loken(it), 9030)nint
it=it+l
read(token(it), 9040)va12
vall =val( nval)
do i=l,nint
nval=nval+ I
c
val(nval)=vall +(val2-vall )*iI(nint+ 1.0)
val(nval)=vall *exp(alog(va12/vall)*i/(nint+ 1.0)
enddo
nval=nval+I
val(nval)=vaI2
it=it+1
C**********************************************************************
C
C Special symbol = m
C m niDt vall 'val2 = Delivers the midpoints of NINT regions
C
between VALl and VAL2 (results in NINT
C
entries)
C
C**********************************************************************
elseif(token(it)(I: I ).eq.'ml)then
if(10klen(it).cq.1 ) then
it=it+1
clse
token(it)(l :32)=token(il)(2: 32)
endif
read(10ken(it),9030)ninl
it=it+l
read( token(it), 9040)vall
it=it+l
read(10ken(it),9040)vall
dval=(vaI2-vall )/float(nint)
vall =vall-dval*O.5
do i=l,nint
nval=nval+ I
vall =val 1+dval
val (nval)=valI
enddo
it=it+1
e1sc
nval=nval+ 1
read(token(it),9040)val(nval)
9030 format(bn,i20)
9040 format(bn,f20.0)
it=it+l
endif
go to 10
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end
e**********************************************************************
e**********************************************************************
subroutine daisf(atitle,i~il)
C**********************************************************************

e
C Module name:
e DAISF

e
e ealledby:
e DAISe DAISI DAISR

e
C Parameters(value):

e

e External variables - used:
e ATITLE
C*(
e 1ST
1*4
e NTOKE
1*4
e TOKEN (ntokex)
e*32

e
C External variables - set:
e IT
1*4

e

C**********************************************************************
panuneter(ntokex= 100000)
character*32 token
integer*4 toklen
commonltokenlntoke, token(ntokex), toklen(ntokex), irefind
panuneter(nequalx=3000)
character*( *)atitle
character* 32 cleft
commonlequalsfnequal,iequals(nequalx)
if(irefindeq.l )then
irefmd=O
nequal=O
do i=l,ntoke
if(token(i).eq. '=')then
nequal=nequal+ 1
iequaJs(nequal)=i
endif
enddo
endif
do ie= l,nequal
if(iequals(ie).ge.ist)go to 10
enddo
it=O
return
10 do j=ie,nequal
i=iequals(j)
if(token(i-I ).eq.atitie)then
it=i+1
return
endif
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enddo
it=O
return
end

C**********************************************************************
C**********************************************************************
subroutine gttoke(atine)

gttoke 1

C**********************************************************************
C
C Module name:
C GTTOKE
C
C Called by:
C DAISO
C
C COMMON blocks:
C token
C
C Parameters(value):
C
C Ex1ernal variables - used:

C ALIN'E

C*80

C
C External variables - set:
1*4
C NTOKE
C TOKEN (ntokex)
C*32
C TOKLEN (ntokex)
1*4
C

C**********************************************************************
pardmeter(ntokex= 1(0000)
cbaracter*32 token
cbaracter*80 aline
integer*4 toklen
commonltokenlntoke,token(ntokex), toklen(ntokex),irefind
data ifirst/]/
if( ifirst. eq.l )then
ifirst=O
ntoke=O
endif
nchar=80

C**********************************************************************
C
C TOKLEN = Length of token in characters
C

C*********************************************************************
C

C Find the first and last non-delimitors
C

C**********************************************************************
do icol= 1,ncbar
ich=icbar(aline(icol:icol»

C**********************************************************************
C
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C
C

The delimitors are bl~ comma, =, and TAB

C**********************************************************************
if(ich.ne.9.and.ich.ne.32.and.ich.nc.61.and,ich.nc.44)then
do iend=nchar,icol,-1
ich=ichar(al ine(icol :icol»
if(ich.ne.9.and,ich.ne.32.and.ich.ne.61.and.ich.ne.44)go
*
to 10
enddo
endif
enddo

C**********************************************************************
C
C
C

The statement is blank. Rcturn

C**********************************************************************
go to 30
10 ic=icol-I

C**********************************************************************
C
C 1. Locate the next delimitor.
C

C**********************************************************************
20 ic=ic+1
if(ic.gt.iend)then

C**********************************************************************
C
C
C
C

A if you run out of characters, package those you have into
a type 2 token

C**********************************************************************
if(aline(icol:icol).eq.'!')go to 30
ntoke=ntoke+ I
toklen(ntoke)=iend-icol+ 1
token(ntoke)=aline(icol:iend)
go to 30
endif
ich=ichar(aline(ic:ic»

C**********************************************************************
C
C
C

The delimitors are blank, comma, =, and TAB

C**********************************************************************
if(ich.eq. 9 .or.ich.eq.32.or.ich.eq.61.or.ich.eq.44)then

C**********************************************************************
C
C 2. Package the previous characters (if there are any) into
C
a type 2 token
C

C**********************************************************************
if(icoJ .ne.ic)then
if(aline(icol:icol).eq.'I ')go to 30
ntoke=ntoke+ 1
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tolden( ntoke)=ic-ico1
token(ntoke)=aline(icol:ic-l)
endif

C**********************************************************************
C
C
C

If it was an equal sign,. add a token with the equal in it

C**********************************************************************
if(ich.eq.61)then
ntoke=ntoke+ 1
token(ntoke)=1='
tolden( ntoke)= 1
endif

C**********************************************************************
C

C 3. Find the next non-blank and set as ICOL
C

C**********************************************************************
do iool=ic+ l,iend

C**********************************************************************
C

C

A If all went well, loop back to 1.

C

C**********************************************************************
if(aline(iooI:icol).ne! ')then
ic=icol-l
go to 20
endif
enddo

C**********************************************************************
C
C

B. If you run out of characters~ return

C

C**********************************************************************
go to 30
endif

C**********************************************************************
C
C
C

Keep collecting characters

C**********************************************************************
go to 20
30 return
end

C**********************************************************************
C**********************************************************************
function

leng(~lim)

C**********************************************************************
C

C Module name:

C LENG
C
C External variables - used:
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C A
C LIM

C*64
1*4

C

C Internal variables:
C LENG
C

1*4

C**********************************************************************
character* 1 a(*)
do leng=lim,l,-l

if(a(leng).ne.' '.and.a(leng).ne.char(9»return
enddo
leng=O
return

end
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AL2 DRIP
program drip
character*8 hname,huse(2)
character*8 date, user ,charge,case, time
character*8 titJ(l2)
character*60 file1
C***********************************************************************

C
C

C

*
Reads DORT output in the VARFLM format

*

*

C***********************************************************************
write(* ,9010)
9010 format(!6x,'What is the OORT flux ou','tput file name?'/)
read(*, '( a60Y)file 1
open(3 ,file===file l,status='old' ,form='unfonnatted')
open( 1,file==='dortread.out',status='Wlknown',form='formatted')
open(2,file==='do rtread. dos', status='Wlknown',form='formatted')
C***********************************************************************
C
*
Read FILE IDENTIFICATION
C
*
C
*
C***********************************************************************
read(3)hname,(huse(i),i= 1,2),ivers
write(I,902 O)hname, (huse(i),i= 1,2),ivers
9020 format(12x,'FiJe name ==> ',a8l2x,'User identification ==> ',a6,
*a6!9x,'File version ==> ',i6)
C***********************************************************************
C
*
C Read FILE LABEL
*
C
*
C***********************************************************************
read(3)date,uscr,charge,case,time,(tit1(i),i= 1,12)
write(I,9030)date,user,charge,case,time,(titl(i),i=1,12)
write(2,9040)date,user,charge,case,time,(tit1(i),i= 1,12)
9030 format(!8x,'Date ==> ',a8/8x,'User ==> ',a8/6x,'Charge ==> ',a8!
*8x:Case ==> ',a8/8x,'Time ==> ',a8111x:Title ==>'l2x,a6,a6,a6,
*a6,a6,a6,a6,a6,a6,a6,a6,a41)
',a8f!',8x,'user ==> "a8!'!',6x,
9040 formatC!',8x,'date
*'cbarge ==> ',as!'f',Sx,'case ==> ',as!'!',Sx,'time ==> ',as!'!'!
*'! title ==>'f'! ',a6,a6,a6,a6,a6,a6,a6,a6,a6,a6,a6,a4)
C***********************************************************************.
C
*
Read FILE CONfROL
C
*
C
*
C***********************************************************************
read(3)igm,neutjm,~ima,mma,ism,imsism,isbt,iter,(idum,i= 1,15)
write( 1,9050)igm,neutjm,lm,ima,mma,ism,imsism,isbt,iter
write(2,9060)igm,neutjm,lm,ima,mma,ism,imsism,isbt,iter
9050 format(21x,'No. of energy groups ==>',lx,i6123x,
*'Last neutron group ==> ',i6120x,'Number of J intervals ==','>',
*i6/7x,'Maximum length of moment',lx,'expansion ==> "i6!20x,
*'Number of I intervals ==', '> ',i6/12x,
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*'Number of boundary direc':tions ==> ',i6116x,
*'Number of I-boundary set','s ==> "i6114x,
*'Total number ofI-inteN','als ==> ',i6/14x,
*'J-set for system boundar','ies ==> ',i6I2x,
*IOnter iteration no. when',lx,'fluxes written ==> ',i6)
9060 format('!'/'!',21x,'no. of energy groups ==>',1~i6f!',23~
*'last neutron group ==> ',i6f!',20~'number ofj inteNals ==',
*1> ',i6f!',7x,'maximum length of moment', l~'expansion ==> ',361
*'!',20x,'number of j intervals ==','> ',i6f!'J2~
*'number of boundary direc','tions ==> ',i6f!',16~
*'number ofi-boundary set','s ==> ',i6f!',14~
*'total number of i-inteN','als ==> ',i6f!',14~
*'i-set for system boundar','ies => ',i6/'!',2~
*'outer iteration no. when'Jx,'lluxes written ==> ',i6)
write(2,9070)igm,neutjm,mma
9070 format(/'!'/'! IGM is number of energ','y groups'f!',2x,
*'MMA is number of angles'/'!'/lx:igm = ',i511~
*'last_Deutron.-COup ',i5/l~'11Z = ',i5/1~'mma = ',i5)
call doit(igm,ismjm,mma,isbt,neut)
call pfstop
stop
end
C***********************************************************************
C***********************************************************************
subroutine doit(igm,ismjm,mma,isbi,neut)
parameter(nscrx=300000)
parameter(ncscrx= 10000)
character* 1 zca
commonlscrchlnscr,za(nscrx),izzz1 ,izzzm
commonlcscrchlncser,zca( ncserx),i7zzem
data ifi rstlll
nscrO=nscr
ncscrO=ncscr
klmbig=ialc8«igm),llmbig
')
kimbis=iale8«ism), 'imbis
I)
kiset=ialc8((jm)/iset
I)
kz=iale8«(jm+I),'z
')
kr=iale8«3000)*(ism),'r
')
call zdoit(igm, ismjm,mma,isbt,neut,za(klmbig),za(kimbis),za(
*kiset),za(kz),za(kr»
nscr=nser(}
ncscr=neser(}
return
end
C***********************************************************************
C***********************************************************************
subroutine zdoit(igm,ismjm,mma,isbt,neut,lmbig,imbis,iset,z,r)
integer Imbig(*),imbis(*),iset(*)
real z(*),r(3000, *)
character*60 file 1
C***********************************************************************

C

*
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C
Read FILE INTEGER PARAMETERS
*
C
(Will not print l:x:'x;ause I do not use them)
*
C
*
C***********************************************************************
read(3)(lmbig(ig),ig=l,igm),(imbis(is),is=1,ism),(isetG)j=ljm)
1mbigx=O
do 10 ig=l,igm
if(lmbig(ig). gt. I mbigx)lmbigx= I mbig(i g)
10 continue
imbisx=O
do 20 i= l,igm
if(imbis(i).gt.imbisx)imbisx=imbis(i)
20 continue
write(2,90 10)imbis(isbt)
9010 format(2x:nr = ',i5)
C***********************************************************************

*
*
*

C
C

Read FILE REAL PARAMETERS

C

C***********************************************************************
read(3)(z(j)j= Ijm+ 1),«r(i,is),i= 1,imbis(is)+ 1),is= l,ism),(
*ener,ig= 1,igm),emin,cneut,ev,devdk,efik,powcI,(dumrl,i=1,13)
writc(2,9020)(z(i),i= 1jm+1)
9020 format(lx,'z ='/(Ix.,Opf9.4, lx.,Opf9.4, lx.,Opf9.4, lx.,Opf9.4, Ix.,
*Opf9.4, Ix»
write(2,9030)(r(i,isbt),i= 1,imbis(isbt)+])
9030 format(lx,'r ='/(lx.,Opf9.4, lx.,Opf9.4, Ix,Opf9.4, Ix.,Opf9.4, Ix.,
*Opf9.4, Ix»
write(* ,9040)
9040 format(/3x,'What is the input file t','hat contains the (r,z)
*Ioints desired?'/)
read(*, '(a60Y)file 1
call daiso(fiI e 1, 1, 10000)
call dcount(,points',ndes, 1)
ndes=ndesl2
call rdfl1L~(igmjm,imbisx.,imbis,iset,mma,is~neut,r,z,ndes)
return
end
C***********************************************************************
C***********************************************************************
subroutine rdflux(igmjm,imbisx.,imbis,iset,mma, is~neut,r,z,
*
ndes)
parameter(nscrx= 300000)
parameter(ncscrx= 10000)
character* I zca
common/scrch/nscr,za(nscrx),izzz 1,izzzm
common/cscrch/ncscr,zca(ncscrx),izzzcm
data ifirstll/
nscrO=nscr
ncscrO=ncscr
kflurn=ialc8((imbisx)*(jm)*(igm), 'flurn
')
kdose=ialc8((imbisx)*(jm)*(3 ),'dose
')
kdneut=ialc8«igm),'dneut
')
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p"

kfdose=ialc8( (igm), '[dose
')
kden=ialc8( (imbisx)*(im):.'den
I)
kzdes=ialc8((ndes), 'zdes
')
krdes=ialc8«ndes),'rdes
')
kpoints=iale8«ndes*2),'points
')
kides=iale8«ndes)/ides
')
kjdes=ialc8«ndes),jdes
')
call zrdfiux(igmjm,imbisx,imbis,iset~mma,isbt,neut,r,z,ndes,za(
*k.f1um),za(kdose),za(kdneut),za(kfdose),za(kden),za(kzdes),za(
*krdes),za(kpoints),za(kides),za(kjdes»
rdtlux 2
nscr=nscrO
ncscr=ncserO
return
end
C***********************************************************************
C***********************************************************************
subroutine zrdfiux(igmjm,imbisx,imbis,iset,mma,isbt,ncut,r,z,
*
ndes,fium,dose,dneut,fdosc,den,zdes,rdes,
*
points,idesjdes)
real flum(imbisxjm, *),dose(imbisxjm, *)
real dneut(*),fdose(*),den(imbisx, *)
real zdes(*),rdes(*),points(*)
integer ides(*)Jdes(*)
character*32 drf
character*60 filel
character*80 file,title
real r(*),z(*),rO(2),zO(2)
integer imbis(*),iset(*)
call daisr('pointsl,0 ,ndes*2,points, I)
do ]0 i=l,ndes
rdes(i)=points(2*i-l )
zdes(i)= poi nts(2* i)
10 continue
do 20 i=l,igm
dneut(i)= I.
20 continue
C***********************************************************************

C
C

*

THE NEXT FACTOR IS A HARDWIRED SCALING FACTOR

C

*
*

C***********************************************************************
fact= «91.3*91.3)/(53.66*53.66»*(16666.67)

write(* ,9010)
9010 fonnat(/3x,'What is the file name fo','r the dose response fune',
*'tions'l'1)
read(*, '(a60)')filel
if(filel.ne. ")thcn
call dclear
call daiso(file 1,1,10000)
call daisr('drf,O,igm,dneut,I)

16

else
print*: What group do you want?'
read(*, '(bn,i] O)')igdes
do 30 i= I ,igm
dneut(i)=O
30 continue
dneut(igdes)= 1.
endif
do 50 i= 1,imbisx
do40j=ljm
dose(ijJ)=O.
dose(ij,2)=0.
40 continue
50 continue
C***********************************************************************
C
*
C Read SCALAR FLUX MOMENTS
*
C
*
C***********************************************************************
imb=imbis(isbt)
do 90 ig= l,igm
print*: Group ',ig
do 80j=ljm
is=iset(j)
ims=irnbis(is)
read(3)(flum(ij~ig),i= l,ims)

do 60 i=l,ims
flum(ij,ig)=llum(ij,ig)*fact
60 continue
do 70 i=l,ims
if(igJe.neut)then
dose(ij,I)=dose(ij,I)+i1um(ij,ig)*dneut(ig)
else
dose(ij,2)=dose(ij,2)+flum(ij,ig)*dneut(ig)
endif
70 continue
9020 format(2x,i3,2x,i3, I x,i3 ,2x,2pc15.8)
80 continue
read(3)
90 continue
write(2,9030)(imbis(iset(j) )j= Ijrn)
9030 format(,!'p!.,3x,'Scalar dose in format'I'!'I'!',6x,
*'((dose(ij),i= I ,imbis(j)', ')j= 1jm)'I'! 'I'! 1,6x,
*'where the IMBIS are the ','number of I nodes'I'!',8x,
*'per J level'l'f'I'!"4x,'Here are the IMBIS value','s -'1'!'/5x,
*'imbis ='/( lx,i4, lx,i4, lx,i4, lx,i4, lx,i4, lx,i4, 1x,i4, lx,i4, I x,i4,
*lx,i4,lx»
write(2,9040)
9040 format(,!'I'!,,3x, 'Neutron scalar doses -'I'!'/2x,'n_dose =')
do 100j=ljm
zmid=0.5*(z(j)+z(j+ I»
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write(2,90 50)zmi<L (dose(ij, 1),i= l,imbis(iset(j»)
100 continue
9050 formatC!',2x,'Height ',Opfl2.5/(lx,2pel1.4,lx,2peI1.4,lx,
*2pel 1.4,1x.2pel 1.4, 1x.2pell.4»
write(2,9060)
9060 fonnat('!'!,!"3x,'Gamma scalar doses -'f!'/2x,'!Ldose =')
do 110 j=ljm
zmid=O.S*(zG)+zG+ I»
write(2,90SO)zmi<L(dose(ij,2),i= l,imbis(iset(j»)
110 continue
C***********************************************************************

C

*

C Combine neutron and gamma into a total dose
*
C
*
C***********************************************************************
do 130j=ljm
do 120 i= 1,imbis(iset(j»
dose(ij,3 )=dose(ij, 1)+dose(ij,2)
120 continue
130 continue
C***********************************************************************
C
*
C For each of the desired points
*
C
*
C***********************************************************************
nz=jm
nr=imbisx
do 210 id=l,ndes
write(* ,9070)i<Lrdes(id),zdes(id)
9070 format(!'========================', '========================',
* '=============='//3x,'Desired point #',i4,2x,'(',Opf9.4,',',
* Opf9.4,')'1)
C***********************************************************************
C
*
C
Find the (ij) point
*
C
*
C***********************************************************************
if(rdes(id).lt.r( 1).or.rdes(id).gt.r(nr+ 1»then
write(* ,9080)rdes(id),r( 1),r(nr+ I)
9080 format(/2x,'Listen, you dwmny!',3x,'The desired R point, .,
* Opf9.S/4x,'is outside the data rang','e ==> ("Opf9.S,', "
* Opf7.3,')'I/Sx,'Ignoring that poin!...'1)
go to 200
endif
if(zdes(id).lt.z(I).or.zdes(id).gt.z(nz+ 1»then
write(* ,9090)zdes(id}.z( 1),z(nz+ I)
9090 fonnat(/2x,'Listen, you dummy!"3x,'The desired Z point, ..
* Opf9.5/4x:is outside the data rang','e ==> C,OpJ'J.S:, ..
* Opf7.3:)'IISx,'Ignoring that point... 'I)
go to 200
endif
do 140 ir=1,nr
if(rdes(id) Jt.r(ir+l)go to ISO
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140 continue
150 i=ir
do 160 iz=I,nz
if(zdes(id}.lt.z(iz+ 1»go to 170
160 continue
170 j=iz
write(*.,9100)ij
9100 format(/9x,'The point is in cell ("i4::,i4:)'1)
C***********************************************************************
C
*
Print the table
C
*
C
*
C***********************************************************************
tdos=O.
do 180 ig=I,igm
fdose(ig)=11um(ij,ig)*dncut(ig)
tdos=tdos+fdose(ig)
180 continue
write(* ,9110)
do ]90 ig=I,igm
perc=fdose(ig)/tdos* 100.
if(perc.gt.0.)write(*,9120)ig,flum(ij,ig),fdose(ig),perc
9110 format(l9x,'Group"5x, 'Flux', I Ox/Dose', 9x., '%'/9x,
* '===== ==========
,'========== ======')
9120 format(9x,i4,2x,lpeI3.6, Ix.,lpeI4.7,Ix.,Opffi.2)
190 continue
200 continue
210 continue
C***********************************************************************

C

*

C Make the dose map
*
C
*
C***********************************************************************
print*: What do you want the .PS dos','e file to be'll
read(*, '(a30)'}fiJe
title='Dose map for file 'llfile(l :30)
nxO=1
nyO=1
rO(I)=r(J)
rO(2)=r(nr+ 1)
zO(l)=z(l)
zO(2)=z(nz+ 1)
do 230 i= I ,nr
do 220 j=I,nz
den(ij)=alog(dose(ij,3»
220 continue
230 continue
calJ makeps(rO,zO.,nxO,nyO.,den,r,z,nr,nz.,title, file, 1)
return
end
C***********************************************************************
C***********************************************************************
subroutine makeps(xO,yO.,nxO,nyO,den,x.,y,nx.,ny,titie,fJle,inonn)
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parameter(nscrx=300000)
parameter(ncscrx= 10000)
character* 1 zca
common/scrch/nscr,za(nscrx),izzzl,izzzm
common/cscrch/ncser,zca( ncscrx),izzzcm
data ifirstlll
nscrO=nscr
ncscrl)=ncscr
kcolor=ialc8«nx) *(ny),'color
I)
call zmakeps(xO,yO,nxO,nyO,den,x,y ,fiX,ny, title,file,inonn,za(
*kcolor»
nscr=nscrO
ncscr=ncserO
return
end
C***********************************************************************
C***********************************************************************
subroutine zmakeps(xO,yO,nxO,nyO,den,x,y,nx,ny,titJe,file,inonn,
*
color)
real color(nx, *)
real xO(nxO+ 1),yO(nyO+ 1)
real x(nx+ 1),y(ny+ 1),den(nx,ny)
character*80 titie,file,aline
C***********************************************************************

*

C
C

Sort tile material densities

*

*

C

C***********************************************************************
wtmax=-IOOOOOOO()O.

do 20 j=l,ny
do 10 i=l,fiX
if(den(ij).gt. wtmax)wtmax=den(ij)
10 continue
20 continue
if(inorm.eq.O)then

wtmin=O.
else
wtmin= 1000000000.
do 40 j=l,ny
do 30 i=l,nx
if(den (ij).lt. wtmin)wtmin=den(ij)
30 continue
40 continue
endif
if(wtmax.1e.wtmin)wtmax=wtmin+ 1.

do 60j=1,ny
do 50 i=l,nx
frac=(den(ij)-wtmin)/(\\'tmax-wtmin)
color(ij)= I.-frac
50 continue
60 continue
C***********************************************************************
80

C
C

*
*
*

Initialize the DRAW subroutines

C

C***********************************************************************
call drbegin(xil(l),yO(l),xil(nxO+ l),yO(nyO+ l),title,file)

C***********************************************************************

*
*

C
C

Draw the calculational cells

*

C

C***********************************************************************
can drthick(. 001)
call drtype('dasbed')
do 80 j=l,ny
do 70 i=l,fl.x
call drfbox(x(i),y(j),x(i+ 1),y(j+ 1),color(ij»
70 continue
80 continue
can drtype('solid')

C***********************************************************************
C
C
C

*
*
*

Draw the bounding box

C***********************************************************************
call drbox(xO(l),yO(l),xil(nxO+ 1),yO(nyO+ 1»

C***********************************************************************
C
C
C

*
*
*

Draw the boxes of original mesh

C***********************************************************************
density=l.
do 100 i=l,nxO
do 90 j= 1,nyO
ij=nyO+l-j
call drbox(xO(i),yO(j),xO(i+ 1),yO(j+ 1»
90 continue
100 continue

C***********************************************************************
C
C

*
*
*

End the DRAW subroutine set

C

C***********************************************************************
call drend
aline='ghostview 'llfile(1 :lcng(file,32»/1' &'
call system(aline)

return
end

C***********************************************************************
C***********************************************************************
function ialc8(nn,avar)
cbaracter* 12 avar
paramete r(nscrx= 3000(0)
parame1er(ncscrx= 10000)
cbaracter* 1 zca
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common/scrchlnscr,za(nscrx),izzzl,izzzm
common/cscrchlncscr,zea(ncscrx),izzzcm
if(nscr.eq.O)tben
nscr-=1
izzzl=1
izzzm=1
endif
ialc8=nscr
llscr-=nscr+nn
if(nscr.gtnscrx)lhen
write(*,90 10)avar,nn,nscr
9010 format(31h No more REAUINT scratch room.,Th Var ,a,6h Leng,
* i9, 13h Requested = ,i9)
stop
endif
if( nscr.gt.izzzm)izzzm=nscr
return
end
C***********************************************************************
C***********************************************************************
function icalc8(nn)
parameter{nscrx= 300000)
parameter(ncscrx= 10000)
character* 1 zea
common/scrchlnscr,za(nscrx),iz7..z 1,izzzm
common/cscrchlncscr,zea(ncscrx),izzzcm
if(ncscr.eq.O)tben
ncscr-=1
izzzcm=l
endif
iealc8=ncscr
ncscr-=ncscr+nn
if(ncscr.gt.ncscrx)thcn
write(*,9010)
9010 format(50h There is not enough CHAR scratch room. Stopping.)
stop
endif
if(ncscr.gt.izzzcm)izzzcm=ncscr
return
end
C***********************************************************************
C***********************************************************************
subroutine pfstop
parameter{nscrx=300000)
parameter(ncscrx= 10000)
character* 1 zea
common/scrchlnscr,za(nscrx),izzzl,izzzm
common/cscrchlncscr,zea( ncscrx),izzzcm
ratio 1=(izzzm* I. )/(nscrx* 1.)* 100.
ratio2=(izzzcm* l.)/(ncscrx* L)* I 00.
write{* ,9010 )izzzm,nscrx,ratio I
9010 format{/ITh OORTREAD used ,ilO,8h out of ,il0,
*25h real/integer variables (,f8.3,2h%))
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wrilC(* ,9020)izzzcm,ncsc~ratio2

9020 fonnal(l2x,5h and ,ilO,8h out of ,iIO,12h characters ,12x,lh(,ffi.
*3~2h%)/)

return

end
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AI.2 DRIP

program flip
charactcr*6 hname,huse(2)
character*8 date, user, charge, case, time
charactcr*8 titl(12)
character*60 file 1
C***********************************************************************
C
C

*
*
*

DELETE THE NEXT LINE. AERS

C

C***********************************************************************
filel='/SCItchlnukc/oldfort.36'

getdo

open(3 ,file=file 1,status='old',form='unformatted')
open( 1,file='temp9 .out',status='unknown',form='formatted')
open(2,filc='temp9.dos',status=lunknown',form='formatted')
open(4,file='fort.36',status='unknown',form='unformatted')
C***********************************************************************
C
C

*
*
*

Read FILE IDENTIFICATION

C

C***********************************************************************
read(3)hnarne,(huse(i),i= 1,2),ivers
write(4)hname,(buse(i),i= 1,2),ivers
write(l,9020)hname,(huse(i),i=1,2),ivers
writc(* ,9020)hname, (huse(i), i= 1,2),ivers
9020 format(12x,'File name ==> ',a812x.,'User identification ==> ',a6,
*a6/9x,'File version ==> ',i21)
C***********************************************************************

*
*
*

C

C

Read FILE LABEL

C

C***********************************************************************
read(3)date,user,charge,case,time,(tit1(i),i=1,7)
write(4)date,user,charge,case,time,(titl(i),i= 1,7)
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write(1,9030)date,user,charge,case,time,(titl(i),i= 1,7)
write(2,9040)date,user,charge,case,time,(tit1(i),i= 1,7)
write(* ,9040)date,user,charge,case,time,(titl(i),i= 1,7)
9030 format(/8x,'Date ==> "a8/8x,'User ==> ',a8/6x,'Charge ==> "a81
*8x,'Case ==> ',a8/8x,'Time ==> ',a8//1x,'Title ==>'/2x,a6,a6,a6,
*a6,a6,a6,a6,a6,a6,a6,a6,a41)
9040 formatCf,,8x,'date ==> "a81'!',8x,'uscr ==> \a81'!',6x,
*'charge => "a8/'!"8x,'case ==> "a8!,!"8x,'time ==> ',a8!,!11
*' f title ==>'/' f ',a6,a6,a6,a6,a6,a6,a6,a6,a6,a6,a6,a4)
C***********************************************************************
C
C

*
*
*

Read FILE CONTROL

C

C***********************************************************************
read(3)igmjrn,ima,mma,nintsr,njntsr,(idum,i=1,19)
write(1,9050)igmjm,ima,mma,nintsr,njntsr
write(* ,9060)igmjm,ima,mma,nintsr,njntsr
write(2, 9060)igmjm,ima,mma,nintsr,njl1tsr
9050 format(21x,'No. of energy groups ==>',lx,i6/20x,
*'Number of J intervals ==','> ',i6/20x,
*'Number of I intervals ==':> ',i6/12x,
*'Numberofboundary direc':tions ==> ',i6113x,
*'Number of I-boundary sou','rces ==> "i6/13x,
*'Number of J-boundary sou','rces ==> "i6)
9060 format('!',2Ix,'No. of energy groups ==>', lx,i6I'f',20x,
*'Number of J intervals ==','> ',i6/'!',20x,
*INumber of I intervals =="'> ',i6/'f,,12x,
*'Number of boundary direc','tions ==> ',i61'!',13x,
*'Number of I-boundary sou','rces ==> ',i6f!',13x,
*'Number of J-boundary sou','rees ==> ',i6)
CALL DAISO('readflux.inp', 1,

10000)

CALL DCOUNT('rold' ,nrold,l)
CALL DCOUNTCmew',nrnew,l)
nmew=nrncw-l
nrold=nroJd-1
85

if(nrold.ne.IOO)then
print *,' rold must have 101 values'
CALLPFSTOP
STOP
endif
write(4)igmjm,nrnew,mm3;nintsr,njntsr,(idum,i=I,19)
call

doit(i~ismjm,mma,im3;nrold,nrnew)

CALLPFSTOP
STOP
end
C***********************************************************************
C***********************************************************************
subroutine doit(i~smjm,mma,im3;nrold,nrnew)
parameter(nscrx=
parameter(ncscrx=

300000)
10000)

character* 1 zca
common!scrchlnscr,za(nscrx),izzzl,iz:zzm
common!cscrchlncscr,zca(ncscrx),izzzcm
data ifirstJ 11
nscrO=nscr
ncscrO=ncscr
kz=ialc8«(jm+ l),'z
krold=ialc8«101),'rold

')
')

kmew=ialc8«nrnew+ 1),'mew

')

kfluxold=ialc8((mma)*( 100), ':fluxold

')

kfluxnew=ialc8«mma)*(nmew),'fluxnew

')

call zdoit
*(igm,ismjrn,mma,ima,nrold,nrnew,

*za(kz) ,za(krold) ,za(kmew) ,za(kf1u.xold) ,za(kfluxnew»
nscr=nscrO
ncscr=ncscrO
return
end
subroutine zdoit
*(igm,ismjm,mma,ima,nrold,nrnew,
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*z,rold,rnew,fluxold,fluxnew)
real z(*),rold(*),mew(*)
real fluxold(mma, *);fluxnew(mma, *)

character*60 file 1
real temp(96, 100)
c

do i=I,51

c

r(i)=i-1

c

enddo

c

do i=52,61

c

r(i)=r(i-I)+2.5

c

cnddo

c

do i=62,81

c

r(i)=r(i-l)+ 1.25

c

cnddo

c

do i=82,91

c

r(i)=r(i-I)+2.5

c

cnddo

c

do i=92,101

c
c

r(i)=r(i-I)+5.0
enddo
CALL DAISR('£Old',O,IOl ,rold, 1)

do 5001 i=I,IOI
print *,' £old "i,rold(i)
5001 CONTINUE
CALL DAISR(,rnew',O,nmew+l,rnew,l)
do 5002 i= l,nmew+ 1
print *,' r ',i,rncw(i)
5002 CONTINUE
C***********************************************************************

*
*
*
*

C

C
C

R~d~EnnEGERPARAMETE~

(Will not print because I do not use them)

C

C***********************************************************************
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read(3)zO
write(4)zO
write(* ,541 )zO
541 format(17x,'Boundary source taken at',lx,'z = ',0pf8.3)
do 5003 ig= l,igm
read(3)((fluxold(j,i)j= l,mma),i= 1,nrold)

c

write(*,'(i5,lx,fl5.2,eI5.8),)(i,0.5*(rold(i)+rold(i+l»,

c

*fluxold(mma,i),i=l,nrold)

c

Now mix them
do 5004 j=] ,nrold
jf(rold(j).gt.mew(l»go to 31

5004 CONTINUE
31

j=j-l
do 5005 i=l,nrnew
do 5006 k=l,mma
fluxnewCki)=O.

5006 CONTINUE
5005 CONTINUE

c

print *,' j = 'j
do 5007 j= 1,nmew

c

print *,' For i = ',i
nnin=rnew(i)

33

c

rmax=rold(j+ 1)
print *: Is rnew(i+l) > nnax ',rnew(i+l),rmax
if(mew(i+ 1).It.rmax)nllax=mew(i+])
frae=(rmax-rmin)/(mew(i+ l)-rnew(i»

c

print *,' frae is now ',frae

do 5008 k= l,mma
fluxnewCki)=fluxnewCk,i)+frac*fluxold(kj)
5008 CONTINUE

c

print *,' old flux is now "fluxold(mmaj)

c

print *,' new flux is now ',fluxnew(mma,i)
if(rmax.eq.mew(i+ I »then

c

print *,' Go on to ne:x1 i'
go to 32
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endif

j=j+I
if(j.gt.nrold)go to 41
print *,' Go to next j'

c

rm.in=rmax

go to 33
32 CONTINUE
5007 CONTINUE

41

continue
write(*,'(i5,lx,fl5.2,eI5.8)')(i,0.5*(rnew(i)+rncw(i+l»,
*f1uxnew(mma3),i= l,nmew)

write(4)«fluxnew(j,i)j=1,mma),i=1,nrnew)
5003 CONTINUE
zero=O.
c

This writes the gamma groups as zeroes

do 5009 ig= 1,84-igm
write(4)«zcroj= 1,mma),i= 1,nme'w)
5009 CONTINUE
write(4 )fluxnc·w( 1,1 )

close(4)
return
cnd
C***********************************************************************
C***********************************************************************
subroutine rdflux(igmjm,imbisx,imbis3set,mma,isbt,neut,r,z,

*

ndes)

parameter(nscrx=
panuneter(ncscrx=

300000)
10000)

character* 1 zca
common/scrchlnscr,za(nscrx),izzz 1,izzzm
commonlcscrchlncscr,zca( ncscrx),izzzcm

data illrst/II
nscrO=nscr
ncscrO=ncscr
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kflum=ialc8( (imbisx)*(jm)*(igm), 'flum
kdosc=ialc8«imbisx)*(jm)*(3):dose
kdncut=ialc8( (igm), 'dneut

')

kfdose=ialc8( (igm), 'fdose

')

kdcn=ialc8«imbisx)*(jm):den
kzdes=ialc8((ndes) ,'zdes

')

krdes=ialc8«ndes):rdes

')

kpoints=ialc8((ndes*2), 'points
kides=ialc8«ndes):ides

')

kjdes=ialc8«ndes),Jdes

')

')
')

')

')

call zrdllux
*(igmjm,imbisx, imbis,iset,mma,isbt, ncut, r,z,
*

ndes,

*Za(kflum),za(kdose),za(kdneut),za(kfdose),za(kdcn) ,za(kzdes) ,
*za(krdes),za(kpoints),za(kides),za(kjdes»
nscr=nscrO
ncscr=ncscrO
return
end
subroutine zrdllux
*(igmjm,imbisx,imbis,iset,mma,isbt,neut,r,z,
*

ndes.,

*flum,dose,dneut,fdose,dcn,zdes,rdes,points,idesjdes)
real flum(imbisxjm, *),dosc(imbisxjm, *)
real dneut(*),fdose(*),den(imbisx, *)
real zdes(*),rdes(*),points(*)
integer ides(*)jdes(*)

charactcr*32 drf
character*60 file!
character*80 file,titie
real r(*),z(*),rO(2),zO(2)
integer imbis(*).,iset(*)
CALL DAlSR('points' ,0,ndes*2,points, 1)
do 5010 i=l,ndes
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rdes(i)=points(2*i-l)
zdcs(i)=points(2*i)
5010 CONTINUE
do 5011 i=I,igm
dneut(i)= 1.
5011 CONTINUE
C***********************************************************************

*

C
C

THE NEXT FACTOR IS A HARDWIRED SCALING FACTOR

*
*

C

C***********************************************************************
filct=(91.3 *91.3)/(53.66*53.66)
C***********************************************************************
write(*,9010)
9010 format(/3x,'What is the file name fol,'r the dose response func',
*ltions?'1)
read(* ,'(a60)')filel
if(file I. ne. ")then
CALLDCLEAR
CALL DAISO(filel,l,

10000)

CALL DAISRCdIf ,O,igm,dneut, 1)
else
print*: What group do you want?'
read(*,'(bn,iIO)')igdes
do 5012 i=l,igm
dneut(i)=O
5012 CONTINUE
dneut(igdes)= l.
endif
do 5013 i=I,imbisx
do 5014 j=ljrn
dose(ij,I)=O.
dose(ij,2)=0.
5014 CONTINUE
S013 CONTINUE
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C***********************************************************************
*

C
C

*

Read SCALAR FLUX MOMENTS

*

C

C***********************************************************************
imb=irnbis(isbt)

C***********************************************************************
C***********************************************************************
do 5015 ig=l,igm
print*,. Group "ig
do 5016 j=ljrn
is=iset(j)
ims=irnbis(is)
read(3)(flum(ij,ig),i= 1,ims)
do 5017 i=l,ims
flum(ij,ig)=fium(ij,ig)* fact
5017

CONTINUE

do 5018 i=1 ,ims
if(igJe.neut)then
dose(ij, 1)=dose(ij, I )+flum(ij,ig)*dneut(ig)
else
dose(ij,2)=dose(ij,2)+flum(ij,ig)*dncut(ig)
endif
5018

CONTINUE

C***********************************************************************

*

C
C

*

write( 1, 9030)(igj,i,flum(ij),i= 1,ims)

*

C

C***********************************************************************
9020 format(2x,i3.2~i3, IX,i3 ,2~2pe] 5.8)
5016 CONTINUE
read(3)
5015 CONTINUE
write(2,9030)(imhis(iset(j»j=ljrn)
9030 formatC!'I'!,,3x,'Scalar dose in formatl/ltll't"6~
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*'( (dose(ij),i= 1,irnbis(j)', ')j= 1jm)'l'! '1'!',6x,
*'where the IMBIS are the ':number of I nodes'I'!',8x,
*'per J level'P!'/'!,,4x,'Here are the IMBIS valuc','s -'1'!'/5x,
*'imbis ='/( IX,i4, I x,i4, I x,i4, lx,i4, IX,i4, lx,i4, IX,i4, lx,i4, I x,i4,
*lx,i4,lx»
write(2,9040)
9040 format(,!'P!,,3x, 'Neutron scalar doses -'I'!'/2x,'n_dose =')
do 5019 j=ljm
zmid=O.5* (z (j)+z(j+ I»
write(2,90 5O)zmid,(dosc(ij, l),i=l,imbis(isel(j)) .
5019 CONTINUE
9050 format(,!,,2x,'Height

',Opfl2.5/(lx,2pcl 1.4,1 x,2pe I 1.4, lx,

*2pell.4, 1x,2pel1.4, 1x,2pell.4»
write(2,9060)
9060 format(,!'P!',3x,'Gamma scalar doses -'I'!'/2x,'g_dose =')
do 5020 j=ljm
zmid=O.5*(z(j)+z(j+ I»
write(2,9050)zmid,(dose(ij,2),i=1,imbis(iset(j»)
5020 CONTINUE
C***********************************************************************

*

C
C

*
*

Combine neutron and gamma into a total dose

C

C***********************************************************************
do 5021 j= ljm
do 5022 i=l,imbis(iset(j»
dose(ij,3 )=dose(ij, 1)+dose(ij,2)
5022 CONTINUE
5021 CONTINUE
C***********************************************************************

c
C

*
*
*

For each of the desired points

C

C***********************************************************************
nz=jm
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nr=imbisx
do 5023

id=l~ndes

write(* ,9070)i~rdes(id),zdes(id)
9070 fOl1llat(f!=======================', '========================',
*1==============1113x,'Desi red JX)int #',i4,2x,'(',Opf9.4,',',
*Opf9.4 ,')'1)
C***********************************************************************

*
*
*

C
C

Find the (ij) JX)int

C

C***********************************************************************
if(rdes(id).It.r( 1).or.rdes(id).gt.r(nr+ 1»then
write(* ,9080)rdes(id),r( 1),r(nr+ 1)
9080 fOl1llat(/2x,'Listen, you dummy!\3x,IThe desired R point, I,
*Opf9.5/4x,'is outside the data rang','e ==> C,Opf9.S,', I,
*Opf7.3,')'1I5x,IIgnoring that JX)int...'f)
go to 30
endif
if(zdes(id).It.z( 1).or.zdes(id).gt.z(nz+ 1»thell
write(* ,9090)zdes(id)~z(1),z(nz+ 1)
9090 fOl1llat(/2x,'Listen, you dummy!',3x,'The desired Z point, .,
*Opf9.5/4x,'is outside the data rang','e ==> (',Opf9.S,', I,
*Opf7.3,')'1I5x,'Ignoring that JX)int.. ..f)
go to 30
endif
do 5024 ir=1,nr
if( rdes(id) Jt.r(i r+ 1))go to 10

5024 CONTINUE
10 i=ir
do S025 iz= I ,nz
if(zdes(id).1t.z(iz+ l»go to 20
502S CONTINUE
20 j=iz
write(* ,91 OO)ij
9100 fOl1llat(/9x,'The JX)int is in cell ("i4,\',i4,'),f)
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C***********************************************************************
C
C

*
*

Print the table

C

*

C***********************************************************************
tdos=O.
do 5026 ig= 1,igm
fdose(ig)==flum(ij,ig)*dneut(ig)
tdos=tdos+fdose(ig)
5026 CONTINUE
write(*,91 10)
do 5027 ig= 1,igm
perc=fdose(ig)/tdos* 100.
if(perc.gt.O.)write(* ,9120)ig,flum(ij.ig),fdose(ig),pcrc
9110 fonnat(/9x,'Group',5x, IFlux', 1Ox/Dose,,9x,'%'/9x ,
*1===== ============= ====1,'==:==:==:==:== =====::::=')
9120 format(9x,i4,2x,lpe13.6,1x,lpeI4.7,1x,Opf6.2)
5027 CONTINUE
30 CONTINUE
5023 CONTINUE

C***********************************************************************

*
*

C

C

Make the dose map

*

C

C***********************************************************************
print* ->' What do you want the .PS dos','e file to be'l'
read(*, '(a30)I)file
title='Dose map for file 'llfile(l :30)
nxO=1
nyO=l
rO(l)=r(l)

rO(2)=r(nr+ 1)
zO(l)=z(l)
zO(2)=z(nz+ 1)

do 5028 i= 1,nr
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do 5029 j=l,nz
den(ij)=alog(dose(ij,3»

CONTINUE
5028 CONI1NUE

5029

can makeps(rO,zO,m(O,nyO,den,r,~nr,nz,title,file, 1)
return
end

C***********************************************************************
C***********************************************************************
subroutine makeps(xO,yO,DxO,nyO,den,x,y,nx,ny,title,file,inorm)

c**********************************************************************#
C
C Module name:
C MAKEPS
C

C Called modules:
C DRBEGIN DRTHICK DRTYPE DRFBOX DRBOX DREND LENG
C

C Called by:
C DETERM DOlT
C
C External variables - used:
C DEN (nx,ny)
R*4
C FILE
C*80
1*4
C INORM
C NX
1*4
C NXO
1*4
C NY
1*4
C NYO
1*4
C
C**********************************************************************
parameter(nscrx= 300(00)
parameter(ncscrx=

1(000)

character* 1 zca
commonlscrchlnscr,za(nscrx),izzz 1,izzzm
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comrnonlcscrchlncscr,zca(ncscrx),izzzcm
data ifirstlll

nscrO=nscr
ncscrO=ncscr
kcolor=ialc8«nx)*(ny):color

I)

call zmakeps
*(xO,yO,l'l"XO,nyO,den,x,y,nx,ny,title,file,inorm,
*za(kcolor»
nscr=nscrO
ncscr=ncscrO
return
end
subroutine zmakeps
*(xO,yO,nxO,nyO,den,x,y,nx,ny,titlc,filc,inonn,
*color)
real color(nx, *)

real xO(nxO+ I ),yO(nyO+ 1)
real x(nx+ 1),y(ny+ 1),den(nx,ny)

character*80 title,fIle,aline
C***********************************************************************

*
*
*

C

C

Sort the material densities

C

C***********************************************************************
\\1rnax=-1000000000.

do 5030 j= 1,ny
do 5031 i=l,lLx
if(den(ij).gt wtmax)wtmax=den(ij)

5031 CONTINUE
5030 CONTINUE

if(inorm.eq.O)then
wtmin=O.
else
wtmin= 1000000000.
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do 5032 j= 1,ny
do 5033 i=l,nx
if(den(ij) .It. wtmin)wtmin=den(ij)
5033

CONTINUE

5032 CONTINUE
endif
if(\\1max.le. wtmin)wtmax=wtmin+ 1.
do 5034 j=l,ny

do 5035 i=l,nx
frac=(den(ij)-wtmin)l(wtmax-wtmin)
color( ij)= 1.-frac
5035 CONTINUE
5034 CONTINUE

C***********************************************************************

*
*
*

C
C

Initialize the DRAW subroutine!;

C

C***********************************************************************
call drbegin(xO( 1),yO( 1),:\.-o(nxO+ 1),yO(nyO+ 1),title,file)

C***********************************************************************

*
*
*

C

C

Draw the calculational cells

C

C***********************************************************************
call drtllick(. 001)
call drtypeCdashed')
do 5036 j= 1,ny
do 5037 i=l,nx
call drfbox(x(i),y(j),x(i+ 1),y(j+ 1),color(ij»
5037 CONTINUE
5036 CONTINUE
call drtypeCsolid')

C***********************************************************************

*
*

C
C

Draw the bounding box
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*

C

C***********************************************************************
call drbox(xO( 1),y0( 1),xO(nxO+ 1),yO(n),O+ 1))

C***********************************************************************

*
*

C

C

Draw the boxes of original mesh

*

C

C***********************************************************************
density=l.
do 5038 i=l,nxO
do 5039 j=l,nyO
.ii=nyO+ l-j
call drbox(xil(i),yO(j),xO(i+l),yO(j+ 1»)

5039 CONTINUE
5038 CONfINUE

C***********************************************************************

*
*
*

C

C

End the DRAW subroutine set

C

C***********************************************************************
call drend

aline='xpsview 'llfile(l :leng(file)2)/l &'
call system(aline)

return

end
function ialc8( nn,avar)
character* 12 avar
parameter(nscrx=
parameter(ncscrx=

30(000)
1(000)

character* 1 zca
commonlscrch/nscr,za(nscrx),izzzl,izzzm
commonlcscrchlncscr,zca(ncscrx),izzzcm
if(nscr.eq.O)then
nscr=1

izzzl=]
99

izzzm=1
endif
iale8=nscr
nscr=nser+nn
if( nser.gt. nserx)then
\\Tite(* ~9999)avar~nn, nser
9999 fonnat(31h No more REAUINT scratch room.,
*7h Var ~~6h Leng ,i9~]3h Requested =

~i9)

stop
endif
if(nscr.gt.izzzm)izzzm=nscr
return
end
function icalc8(nn)
parameter(nscrx=
parameter(ncscrx=

300000)
100(0)

character* 1 zca
commonlscrchlnscr,za(nscrx),izzz 1, iZ7.zm
commonlcscrch/ncscr,zca( ncscrx),uzzcm

if(ncscr.cq. O)then
ncscr=l
v2zcm=1
endif
icalc8=ncscr
ncscr=ncscr+nn
if(ncscr. gt. ncscrx )then
write(* ,9999)
9999 format(50h There is n01 enough CHAR scmtch room. Stopping.)
stop
endif
if(ncscr.gt.izzzcm)izzzcm=ncscr
return
end
subroutine pfstop
panuneter(nSCfX=

300000)
100

parameter(ncscrx=

100(0)

character* 1 zca
commonlscrchlnscr,za(nscrx)~izzz 1,izzzm

commonlcscrchlncscr,zca( ncscrx)~izzzcm
ratio 1=(izzzm *1. )/(nscrx* 1.)* 100.
ratio2=(izzzcm* I. )/(ncscrx* 1.)* I 00.
write(* ,9999)izzzm,nsc~ratio 1

9999 fonnat(/l7h TEMP9

used ,ilO,8h out of ,ilO,

*25h real/integer variables (,f8.3,2h%)
l\Tite(* ,9998)izzzcm, ncsc~ratio2

9998 format(l2x,5h and ,ilO,8h out of ,ilO,
*12h characters, 12x, Ih(,f8.3,2h%)1)
return
end
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Appendix 2
Economics
Table 1. Facility Expenses
Clinical Operations
Labor
Benefits and Taxes
Clinic Overhead
Medica) Supplies
Medical Equipment
Maintenance
Total Clinical Operations

40

1996 dolla rs
4406160
1365910
410879
88647
26594
6298190

Clinical Overhead
Facilities maintainance
Telephone
Utilities
Insurance
Office Supplies
Travel
Meetings and Conferences
Postage and Delivery
Lega) and Professional
Consultants
Licenses and Fees
Information Systems
Maintenance
Employee Development
Total Clinical Overhead

Reactor Operations
SIC Nuclear Engineering
Operations
Nuclear Supplies
Reactor Maintenance
Reactor Overhead
Total Reactor Operations

35459
8865
19946
88647
8865
2659
3546
3546
88647
53188
53188
17729
26594
410879

100000
93080
37232
1195291
1425603
102

Reactor Overhead
Facilities Ma'lntenance
Facilities Rent
Telephone
Utilities
Insurance
Office SuppHes
Travel
Meeting and Conferences
Postage and Delivery
Legal and Professional
Consultants
Licenses and Fees
Information Systems
Maintenance
Employee Development
Total Reactor Overhead

17729
1099996
8865
8865
35459
3546
2659
1330
2659
4432
0
3546
4432
1773
1195291

Expenses
Clinical Operations
Clinical Overhead
Reactor Operations
Reactor Overhead
Research
Total Expenses

6298190
410879
1425603
1195291
4700000
$14029963

Personner
Executive Director
Oep, Executive Director
Administrative Director
Personnel Manager
Patient SelVices Manager
Staff (Emp-1)
Staff (Emp-2J
Accounting
Maintenance (Facility)
Staff (Emp-1)
Staff (Emp-2)
Housekeeping
Staff (Emp-1)
Staff (Emp-2J

203612
179178
179178
105878
105878
40722
40722
105878
52125
28506
28506
57011
36650
36650
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Maintenance (Grounds)
Staff (Emp-1)
Staff (Emp-2)
Patient QA Director
Director of Research
Compound Development
Diagnostic Systems
Nuclear Systems
Medical Sys. and Prac.
Director of Reactor
Operations
Nuclear QA Manager
Reactor Operator (1)
Reactor Operator (2)
Reactor Operator (3)
Staff (1)
Staff (2)
Director of Therapy
Chief of Nursing
Nursing Staff
Therapy Scheduler
Chief of Services
Neurosurgery
Thoracic Surgery
Radiology
Total Personnel Costs

Primary Brain Tumors
Telemedicine Software
linkage
Prequalification
MRI (regular)
MRI (boron)
PET (boron)
Neurosurgery
Operating Theater
Recovery
Hospital (other-2 days)
Compound (Pharmacy)
MRIIPET
Therapy
BNCT
Total Primary Brain Tumor Cost
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52125
28506
28506
105878
203612
81445
81445
81445
81445
179178
105878
81445
81445
81445
52125
52125
203612
154745
195467
52125
0
407224
407224
407224
4406163

1800
1200
18000
42000
48000
300000
60000
60000
30000
30000
179892
770892
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